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Regulations are necessary for the organization of society.  A good regulatory framework 
protects the health and environment of its citizens, contributes to economic growth, and 
promotes investments that will improve a nation’s productivity and thus improve the 
standard of living.  A dysfunctional regulatory system, however, hinders investment, 
productivity and innovation and reduces competitiveness and job opportunity. 
 
One aspect of Canada’s regulatory framework is its mechanism for approving new 
products used for curing or preventing diseases in farm and companion animals.  We at 
the Centre have heard complaints about the approval process across a number of 
Market Access Regulatory Programs for years.  Hence we approached the Canadian 
Animal Health Institute (CAHI) with a proposal to conduct an economic analysis of the 
approval process
1.  The resulting study, the results of which are presented here, had 
two underlying purposes:   
 
1)  Identify the impact of Canada’s product registration system on companies 
operating in the animal health products industry in Canada, and ultimately, 
estimate the magnitude of the economic cost to the agri-food sector and the 
Canadian economy imposed by this system; and  
2)  Offer some alternative, potentially “optimum,” solutions to the system and identify 
the costs/benefits of such a system. 
 
The specific objectives of the project were:   
 
1.  To describe, compare and contrast the agriculture product approval systems in 
the United States, Australia, European Union and Canada with respect to the 
governing authority, structure and responsibility, marketing approval, applicant 
tasks, fees, time to approval and performance indicators. 
2.  To estimate the direct loss to companies, downstream losses to the agriculture 
industry and losses to the Canadian economy resulting from delayed product 
review for five case study products submitted to the Veterinary Drugs Directorate 
(VDD) for approval in Canada. 
3.  To develop recommendations based on the above analysis for improvements to 
the Canadian system. 
 
To meet the objectives outlined above, the project was divided into three stages of work 
that parallel the objectives: 
 
Stage 1 involved a literature review and (in some cases) personal interviews about the 
regulatory system for food animal and companion animal (animal health) product 
                                            
1 This means that about half of the cost of the study was paid for by members of the industry, while the 
other half was paid for by the Centre itself.  The Centre identified assessing the impacts of Canada’s 
regulatory system on Canada’s agri-food competitiveness as one of its major research focuses.  Hence 
we regard it as a priority for investing our own resources. The Competitiveness Impacts of Canada’s Agricultural Product Review 
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approvals for the United States, Australia, European Union and Canada.  The review 
addressed the governing authority, structure and responsibility, marketing approval and 
applicant tasks, fees, approval time and performance indicators.  
 
Stage 2 involved the development of a series of case studies of the applications for 
approval of five products.  The cases were chosen by companies within the industry to 
illustrate their experience with the system.  The cases were also used to provide 
evidence on the economic and other consequences
2 of the Canadian system for animal 
health companies, their customers and the broader economy.  
 
Stage 3 involved designing the ‘optimum’ registration system and estimating the costs 
and benefits of the proposed system to the Canadian economy.  To accomplish this, the 
George Morris Centre conducted a focus group session with key members of the 
industry and government to develop the basic requirements for an ‘optimum’ system.   
 
Comparing the structure and performance of the various national approval systems 
(section 2.0), provided the following insights: 
 
•  There are substantial structural differences in the systems among the countries, 
including internal disciplines designed to facilitate approval processes.   
o  For example, until recently there was no appeal mechanism in Canada 
during the application process or once the drug decisions were made, but 
they exist in other systems.  In December 2003, a blueprint for appeals 
was published by VDD; however, it is not an independent appeal 
mechanism as requested by industry.  There still remains a need for an 
independent dispute mechanism. 
o  For example, there are no mandatory pre-submission meetings (as in the 
EU) for applicants to get an understanding of what is required prior to 
submission.   
•  There are substantial differences in fees charged by regulators.  Canada’s is the 
highest when measured on the basis of market access gained.  
•  There are greater unanticipated delays in the approval system in Canada than in 
the other comparators. 
•  Total elapsed time until a decision is made is the slowest in Canada, by a wide 
margin.  It is understood that, since the commission of this report (January 2003), 
there has been an effort on the part of the VDD to improve this situation but more 
improvements are needed to make this a world-class regulatory environment.  
o  The Canadian system until recently made no commitment about time of 
review decision and does not adhere to its internal administrative 
standards.  A draft management of submission policy document has 
recently been circulated for discussion and includes performance 
standards. 
                                            
2 As will be seen, all of the consequences cannot easily be reduced to dollars and cents, especially in the 
companion animal area where delays in approval can mean suffering and death of people’s pets. The Competitiveness Impacts of Canada’s Agricultural Product Review 
Regulations 
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  Canada has administrative or “provisional” standards of 180 days.  
  US have implemented the Animal Drug User Fee Act (ADUFA) in 
which the legislation will impose performance standards on the 
CVM that are expected to improve the drug approval process to 
180 days, 90% of the time by 2008. 
  Australia aims to finish an approval in 240 days. 
  The EU attempts to complete an approval process in 210 working 
days, not including “clock stop” days. 
o  Actual elapsed time until a decision was made in Canada is not related to 
the administrative standard.  
  Canada: exceeded its 180-day target 87% of time (2002). 
  US:  exceeded its 180-day target 83% of the time (2002). 
  Australia: met its 240-day target 96.2% within timeframe (2001-02). 
  EU: limited data, but in the last 3 yrs has generally been within its 
timeframe of 210 days. 
 
As will become clear in the text, the differences between Canada and the US compared 
to Australia are much greater than the 60-day difference in their standards. 
 
The five case studies were analyzed to estimate the costs imposed as a result of the 
additional time required in Canada to make an approval decision.  The analysis is done 
comparing Canada’s performance against Australia’s 240-day standard, not to the 
internal standard of 180 days.  Costs resulting from delays were categorized into direct 
costs to the company sponsoring the application, indirect costs to the downstream 
industries, which are unable to source the product and its health benefits, and 
opportunity costs to the economy because of foregone economic activity. The three are 
not additive – they are separated for the purpose of providing an idea of the magnitude 
of losses to the different parts of the economy associated with these five cases. 
 
The estimated economic impacts by category, of approval delays beyond 240 days in 
Canada for the five cases were: 
•  Approximately $76 million in direct losses to the participating companies. 
•  Approximately $91 million in indirect costs to the down stream agricultural 
industry.   
•  Approximately $1.8 million in losses to the economy. 
 
With the foregoing as background, a group of industry, and government personnel met 
to develop the desired characteristics of a stringent, yet timely product registration 
program for Canada.  The group came up with a lengthy and detailed set of 
characteristics organized around the following headings that are presented in section 
4.0: 
•  Objectives of the Legislation 
•  Procedures for market approval  
•  Applicant tasks 
•  Costs and Incentives The Competitiveness Impacts of Canada’s Agricultural Product Review 
Regulations 
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•  Transparency 
•  Consistency 
•  Perceived Costs and Benefits 
 
Conclusions and Recommendations 
 
While the foregoing are discussed in detail in section 4.0, one conclusion arrived at by 
the assembled group is inappropriate given subsequent information.  That conclusion 
was that the underlying legislation does not need to change.  Subsequent work by 
Rainnie and the Environmental Commissioner reveals what was already becoming 
evident to the Centre through a number of anecdotal observations – the problems are 
not just in approvals of animal health products.  As Rainnie and the Environmental 
Commissioners reports show, the problem is widespread in reviews of plant 
health products, and in reviews of consumer (companion animal) products.   
 
When one views the entire product approval system, one is left with the impression that 
it is out of the control of Parliament.  The legislation and regulations have been 
developed piecemeal.  There is no – or very little - reference to any economic or trade 
objectives of the legislation.  Product reviewers, therefore, do not balance the narrow 
concept of risk prevention with the promotion of innovative advancements in health 
methodologies and products.  By the same token, there is very little in the legislation 
that allows the public, though Parliament and its organizations such as the Auditor 
General, to hold regulators accountable for the economic consequences of their 
decisions -or non-decisions.  At a time when government says it wants to increase 
“value adding”, “productivity” or “technology”, it must put regulatory processes in place 
that are consistent with its intents.   
 
Therefore, our recommendation below goes farther than did the participants in the 
process for this project.   
 
Changing the System 
 
1.  Parliament needs to change the legislative intent to include a goal of enhancing 
industry competitiveness as well as protecting animals, people and the 
environment.  They are not in conflict – no company will gain economic 
advantage for long by harming animals, people or the environment. In fact, 
everyone we know is looking for advantages by trying to do the right things, in 
part because it is perceived to be part of what most consumers want.  Therefore, 
everyone will welcome an approval system that is tough but fast.   
2.  Parliament needs to extend this change across all product approval legislation, at 
least in the agri-food sector.  The same problems occur for plant health, other 
input supplies and food labelling.  
3.  The system should: 
•  Be transparent – applicants must be able to understand from the 
beginning what information is required to obtain an approval. Therefore, The Competitiveness Impacts of Canada’s Agricultural Product Review 
Regulations 
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the regulatory procedures need to explicitly have clear guidelines for what 
is required of the applicant and what is required of the regulator. 
•  Be consistent – the same things should be expected for a certain type of 
registration every time. The current system is full of arbitrary decisions by 
regulators that mean each application is a new adventure.  
•  Have well-understood timelines. They should be measurable and 
enforceable.  They should likely include a “stop clock” concept so that both 
sides are accountable. 
•  Have clearly defined gates (e.g., specific issues dealt with separately, i.e. 
it should be clear what the procedures and decisions are for trade issues 
separately from efficacy, separately from health, environment, etc.). 
•  Function on fact-based processes. 
•  Be properly resourced by government, including optimum use of 
appropriate outside expertise. 
•  Include independent appeal mechanism(s). 
•  Develop appropriate benchmarks and metrics to measure its performance 
against objectives and compare to best in class. 
 
Process for Change 
 
The process clearly needs to pursue a number of efforts simultaneously: 
 
1.  Most fundamentally, CAHI needs to join forces with other segments of the  
agri-food sector to effect change since all are negatively affected by the larger 
system.  This coalition also needs to get some form of consumer support for the 
principles.  It needs to develop a united front and convince elected government to 
effect the changes. 
2.  Our experience is that the case studies are excellent vehicles to make the issues 
real for people who don’t deal with product registrations every day.  They clearly 
show the faults with the system and the frustrations that result.  In addition, they 
provide a way to describe the magnitude of cost.  A number of them need to be 
done in the other industries to assist in communication from a consistent 
framework. 
3.  In order to move forward, it is likely that the following initiatives need to be taken: 
a.  Contact potential champions among elected representatives to develop a 
strategy for convincing government of the need for change. 
b.  Contact the people in the “Smart” Regulation process to obtain their 
understanding and support (this has already started). 
c.  Bring together the affected industries in a series of conferences to 
establish common ground for the push to get change. The Competitiveness Impacts of Canada’s Agricultural Product Review 
Regulations 
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1.0 Introduction 
 
Regulations are necessary for the organization of society.  A good regulatory framework 
protects the health and environment of its citizens, contributes to economic growth, and 
promotes investments that, in turn, improve a nation’s productivity and improve its 
standard of living.  A dysfunctional regulatory system however, hinders productivity and 
innovation and reduces competitiveness and job opportunity (RIAS Inc.). We would add 
to the RIAS notions that protecting health and environment are not necessarily trade 
offs for competitiveness and innovation.  A regulatory system that is slow and 
burdensome can actually do harm to human health and environment by stifling the very 
innovation that could improve them.  
 
The intent of Canada’s regulatory framework has been to protect Canadians while 
keeping its industries competitive through promoting investments and increasing 
productivity while protecting Canadians.  The system, however, is not functioning well.  
The perceived result is a loss in growth opportunities and competitiveness across many 
sectors, including biotechnology, agri-food and financial services.  In early 2000, the 
Public Policy Forum illustrated this increasing Canadian concern.  The article stated that 
industry participants believe the federal government’s regulatory regime continues to 
put Canadian enterprises at a significant competitive disadvantage and if the current 
system is not reformed, there is a risk that investment and employment will relocate 
outside of Canada.  There is some evidence that this has already started. 
 
One particular example of how the regulatory system hinders the growth of an industry 
occurs in the Animal Health sector, where the product registration procedure causes 
new animal health and companion animal products to be registered at a slower rate in 




A lagging and non-transparent registration system affects company decisions about 
where and when to undertake research and development (R&D), as well as any 
subsequent manufacturing, and hence capital investment, that flows from the research 
and development.  Regulatory processes can affect R&D as well as follow-up 
investment in a number of ways: 
 
  Lack of transparency in requirements for obtaining product approval can cause 
unnecessary difficulty, cost, and delays in meeting the criteria; 
  Inconsistency of application of the requirements can create a moving target that 
is difficult and sometimes impossible to hit; 
  The longer the time taken to obtain approval: 
o  The greater the time to access markets. 
o  The greater the likelihood of new competition entering the market, and 
o  The more costly the process. The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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o  Use of non-regulated products in the form of imports from countries with 
access to innovative animal health management tools. 
  The greater the unpredictability in the application of regulations, the less likely 
that the approval will be obtained and the more likely that investment will occur 
elsewhere. 
  Duplication of requirements can increase costs by orders of magnitude if tests 
need to be replicated needlessly. 
 
Delays in the regulatory process also have downstream impacts on the Canadian 
agricultural industry.  For example, if a product has not been approved in Canada but is 
available in competing countries, the downstream industry in Canada suffers.  
Domestically, Canadian agriculture loses the benefits of the product, for example, 
productivity gains or a potential reduction in the incidence of disease.  Therefore, 
Canadian agriculture also loses competitive advantage internationally. 
 
These problems are amplified when the country in question is a relative “minor use” 
area, as Canada is often classified.  If potential sales are limited by the size of the 
market, a slow and costly product approval system can discourage products from being 
registered.  In turn, this discourages early stage R&D from being in Canada in the first 
place.  Naturally, it may also mean that end users lose the value of improved products 
for some period of time – or forever, if the products are not eventually registered.  This, 
in turn, can create “black markets” for access to non-registered drugs. 
 
It should also be noted that all of the foregoing are not necessarily a problem.  If 
Canada’s regulations were stringent, but the process was transparent and efficient, this 
could actually be an advantage.  It is possible that Canada would become the preferred 
location for R&D, and follow-up manufacturing with its attendant investment, because of 
a regulatory regime recognized around the world as “tough but fast.”  This could provide 
a significant competitive advantage for Canada. 
 
1.1  Purpose and Objectives 
 
Given the problems identified above, there are two underlying purposes to this project:   
 
1.  Identify the impact of Canada’s product registration system on companies 
operating in the animal health products industry in Canada, and ultimately, 
estimate the magnitude of the economic cost to the agri-food sector and the 
Canadian economy imposed by this system; and  
2.  Offer some alternative, potentially “optimum,” solutions to the system and identify 
the costs/benefits of such a system. 
 The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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The specific objectives are:   
 
1.  To describe, compare and contrast the agriculture product review systems in the 
United States, Australia, European Union and Canada
3 with respect to the 
governing authority, structure and responsibility, marketing approval, applicant 
tasks, fees, time to approval and performance indicators. 
2.  To estimate the direct loss to companies, downstream losses to the agriculture 
industry and losses to the Canadian economy resulting from delayed product 
approval for five case study products submitted to the Veterinary Drugs 
Directorate for approval in Canada. 
3.  To develop recommendations based on the above analysis for improvements to 
the Canadian system. 
 
Fundamentally, the project addresses the cost of the above issues and provides 
direction on how to improve procedures so they are aligned with the stated “tough but 
fast” policy.  In addition to these however, the following questions are important 
considerations for this analysis: 
 
1.  What are the costs of the current product approval system to companies that 
provide health products to animal agriculture and companion animal medicine?  
What would be the advantages of a system that is “tough but fast?”  (This could 
be expanded to include crop protection products, feeds, seeds, disinfectants, 
etc.) 
2.  What are the costs to the agri-food sector of the current system and what would 
be the advantages of a faster system?  If products are not available or are 
available more slowly than in competitor countries, then animal (and crop) 
agriculture will benefit from fewer efficiencies in Canada.  This, in turn, means 
that farmers lose. 
3.  What are the impacts on the economy of the current approach?  How much 
investment and employment could result from an improved product registration 
system? 
4.  What needs to change in the Canadian registration system to make it facilitate 
investment and employment rather than discourage it?  What would be an 





To meet the objectives outlined above, the project was divided into three distinct stages 
of work.   
 
Stage 1 involved a literature review and (in some cases) personal interviews about the 
regulatory system for food animal and companion animal (animal health) product 
                                            
3 The Canadian review is of the Veterinary Drugs Directorate within Health Canada and does not include 
a review of the Veterinary Biologics Section of the Canadian Food Inspection Agency. The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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approvals for the United States, Australia, European Union and Canada.  The review 
addresses the governing authority, structure and responsibility, marketing approval and 
applicant tasks, fees, approval time and performance indicators. 
 
Stage 2 estimated the economic cost of the current system.  To accomplish this, we 
gathered information from companies that previously experienced challenges with the 
registration process.  Using information provided by participating companies regarding 
the precise procedures, information and costs required for approval of veterinary or 
agricultural products, individual confidential case studies were developed.   
The framework to estimate and aggregate the economic costs is based on the 
information gathered for the individual case studies and from conversations with 
regulatory personnel (from case study companies).  The model attempts to capture not 
only the direct costs to companies, but also the indirect downstream costs to producers, 
processors and consumers.  Where feasible, projections to the overall cost to the 
economy are made. 
 
Although much more difficult to model, we also incorporate the effects of lost investment 
and lost employment to the Canadian economy as a result of delays in the registration 
system.   
 
Stage 3 involved designing the ‘optimum’ registration system and estimating the costs 
and benefits of the proposed system to the Canadian economy.  To accomplish this, the 
George Morris Centre conducted a focus group session with key members of the 
industry and government to develop the basic requirements for an ‘optimum’ system.  
This information was then used to identify the costs and benefits of the optimum 
system.  In the analysis of the proposed optimum system are the costs to the 
government, as well as potential benefits in terms of tax revenues, investment and 
employment. 
 
It is important to acknowledge that this research reviews a point in time and that 
numerous changes and advancements at the VDD have occurred since the onset and 
development of the research objectives.  These changes have been acknowledged as 
accurately as possible in the document.  However, there are some problems within the 
product review and approval process that continue to plague the Canada system.  The 
recommendations component of Section 5 will identify what is required for Canada to 
have a world-class regulatory system.The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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2.0  Agricultural Product Approval Systems:  United States, Australia, European 
Union and Canada 
 
Section 2.0 describes the registration system for food animal and companion animal 
(animal health) product approvals for the United States, Australia, European Union and 
Canada.  The review discusses the governing authority, structure and responsibility, 
marketing approval and applicant tasks, fees, approval time and performance 
indicators. 
 
2.1 United  States
4 
 
The Food and Drug Administration's Center for Veterinary Medicine (CVM) is 
responsible for assuring that animal drugs and medicated feeds are safe and effective 
and that food from treated animals is safe to eat. This authority is derived from the 
Federal Food, Drug, and Cosmetic Act (1938). The Act was amended in 1968 to include 
sections that specifically address animal drugs. These amendments were designed to 
ensure that animal drugs are safe and effective for their intended uses and that they do 
not result in unsafe residues in foods.  
 
One of CVM's highest priorities is assuring the safety of the food supply.  
 
CVM works to educate consumers as well as the regulated industry; evaluates data on 
proposed veterinary products before permitting them to be marketed; discovers volatile 
marketed products through surveillance programs, and initiates legal action, if 
necessary, to bring violators into compliance with the law; and conducts research to 
support Center activities.  
 
Structure and Responsibility 
 
Before a new animal drug can be marketed in the United States, it must be approved by 
the Food and Drug Administration (FDA) on the basis of quality, safety, and efficacy. 
When the drug is for use in food-producing animals, not only must animal safety be 
demonstrated, but so too must the safety of food products derived from the treated 
animals intended for human consumption.  
 
Once approved products are on the market, the Center monitors the use of the products 
through surveillance and compliance programs. 
 
The Federal Food, Drug, and Cosmetic Act allow the Secretary of Health and Human 
Services to delegate authority to the CVM. Among these re-delegated functions are:  
 
  Authority to approve New Animal Drug Applications and their supplements and 
Abbreviated New Animal Drug Applications (for generic drugs).  
                                            
4 USFDA, 2003 The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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  Authority to issue proposals, notices, and orders relating to refusal to approve 
and withdrawal of approval of New Animal Drug Applications and corresponding 
new animal drug regulations.  
  Authority to approve the use of certain food additives.  
 
The CVM consists of the Office of the Center Director, the Office of Management, the 
Office of New Animal Drug Evaluation, the Office of Surveillance and Compliance and 
the Office of Research. 
 
The major responsibility of the Office of New Animal Drug Evaluation (ONADE) (a 
division of CVM) is to review information submitted by drug sponsors who require 
approval to manufacture and market animal drugs. A new animal drug is deemed 
unsafe unless there is an approved new animal drug application. Virtually all animal 
drugs are "new animal drugs" within the meaning of the term in the Federal Food, Drug, 




ONADE determines whether an animal drug should be approved for marketing. Before 
a new animal drug receives FDA approval, it must be clinically tested for effectiveness 
and safety. If a product is intended for use in a food-producing animal, it must also be 
tested for safety to human consumers, and the edible animal products must be free of 
unsafe drug residues. The sponsor must also develop analytical methods to detect and 
measure drug residues in edible animal products. It is the responsibility of the drug 
sponsor (the individual or firm seeking FDA approval of the drug product) to conduct the 
necessary tests.  
 
ONADE performs the following tasks in their review of applications: 
 
  Determines the adequacy of information submitted for proposed use of 
investigational new animal drugs (INAD).  
  Evaluates the safety and effectiveness of new animal drugs.  
  Evaluates the safety for human consumption of drug residues in food derived 
from treated animals.  
  Evaluates the effect of animal drugs on the environment.  
  Evaluates manufacturing methods and procedures for new animal drug products.  
  Recommends to the Center Director appropriate action on new animal drug 
applications and abbreviated new animal drug applications (for generic drugs).  
  Coordinates the development and implementation of regulations and policies 
pertaining to new drugs intended for animal use.  
 
There are two main processes involved in regulating the interstate shipment of animal 
drug products. The first process, the Investigational New Animal Drug exemption, 
involves the interstate shipment of experimental drugs used for testing in animals. This 
testing may require that drugs be given to animals that will later be used to produce The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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human food products. FDA must ensure that the food products derived from the 
experimental animals are safe for human consumption.  
 
The second process is the New Animal Drug Application (NADA) review. It includes 
evaluating data regarding an animal drug's safety to the treated animal and to humans 
who might consume products from the treated animal, in addition to evaluating the drug 
effectiveness (for the purposes claimed). To be legally marketed, a new animal drug 
product must be approved under a NADA. 
 
ONADE is divided into several different groups charged with the evaluation of both 
INAD and NADA submissions.  Efficacy and safety information for the animals are 
evaluated by two therapeutic use groups (food animals and non-food animals), and by a 
group that evaluates production drugs. There are additional groups responsible for 
reviewing other aspects of submissions. For example, the human food safety group 
evaluates the safety to the public, the user (the producer or veterinarian), analytical 
methods, withdrawal times, and provides the drug tolerances so that safe residue levels 
and conditions of use are provided to the public. The manufacturing chemistry group 
evaluates the manufacturing processes, quality control and environmental safety. The 
biometrics group provides statistical support to ONADE and the rest of the Center. 
 
The various groups in ONADE review the information and any amendments in the 
NADA. A decision is then made to determine whether the information provided in 
submissions concerning the new animal drug illustrates that the product will be safe and 
effective for its intended use. If the information shows the drug is safe and effective, a 
recommendation is provided to the Center Director that the NADA should be approved. 
If the Director agrees, he/she approves the application and a notice of approval is 
published in the Federal Register. 
 
A sponsor must conduct certain tests to show that a drug is safe for the target animal, 
has the intended effect, and that edible products derived from treated animals are safe 
for human consumption. If animals receiving an investigational drug are to be 
slaughtered for consumption, authorization to do so is needed from the FDA. These 
animals must be slaughtered in a federally inspected facility. The USDA, in coordination 
with the FDA, provides a USDA inspector to monitor the slaughter of research animals 
intended for human consumption. 
 
Usually drug approval process begins with the sponsor submitting a request for an 
exemption to use a particular substance for experimental purposes. CVM can grant this 
under an INAD. Once an INAD exemption has been granted according to the 
requirement of the Federal Food Drug and Cosmetic Act (FFDCA), the sponsor must do 
the following: 
 
  Assure the proper and safe packaging and labelling of investigational drugs.  
  Report the names and locations of investigators to whom drugs are shipped.  The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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  Maintain records of all drug shipments and of all reports received from 
investigators.  
  Notify FDA immediately if a safety problem is observed.  
  Notify FDA or USDA prior to slaughter of animals treated with the investigational 
drug.  
  A request for a categorical exclusion from an Environmental Assessment.  
  An important function in the INAD process for all ONADE staff is review of 
submitted protocols for experimental work conducted to provide the necessary 
information needed for the approval of the NADA.  
  A sponsor may submit individual completed technical sections (such as target 
animal safety, effectiveness, human food safety, freedom of information (FOI), 
and labelling) for "phased review" under the INAD, or the entire requirements for 
approval may be provided in one submission as an NADA.  
  An "original" NADA (the initial application for approval of a new animal drug) 
should contain all of the following information:  
o  A signed copy of the FDA 356V (New Animal Drug Application).  
o  A well-organized summary of the information in the application.  
 
When the applicant feels that sufficient data has been generated to establish the safety 
and efficacy of their product, they are ready to apply for approval.  A New Animal Drug 
Application must be submitted in triplicate to the CVM along with all the data obtained 
during the clinical trials. 
 
Approval Time  
 
Approval time can vary greatly depending on the completeness and accuracy of the 
safety and efficacy data submitted. The CVM has a statutory review time of 180 days, 
which implies that an approval decision must be made, or the sponsor must be advised 
why an application cannot be approved (refer to Appendix B for an assessment timeline 
of new drug submissions).  This 180-day timeframe is a provisional timeframe in that 
after the sponsor has been advised; the final decision can often take much longer than 
the 180 days.  The applicant is however, notified of the progress of the application.   
 
Appeals Procedure 
The CVM appeal procedure was developed to deal with problems that occur between 
the sponsor and the group reviewing the application, during the application procedure.  
When a sponsor disagrees with a decision regarding science or policy, he/she may 
submit an appeal in writing to the Division Director responsible for the group reviewing 
the sponsor’s application.  The initial appeal should contain documentation of the 
sponsor’s viewpoint and must not contain new information that has not been reviewed. 
If the issue involves animal safety or effectiveness, the Division Director has the 
responsibility of preparing a written response to the sponsor’s appeal and for obtaining 
the concurrence of his or her Office Director with that response. The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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Fees    
 
On November 18, 2003, “The Animal Drug User Fee Act (ADUFA) of 2003” was signed 
by President Bush.  ADUFA amends the Federal Food, Drug, and Cosmetic Act and 
authorises the FDA to collect fees for certain applications and establishments, products 
and sponsors of those applications in support of the review of animal drugs. 
The driving force for the implementing of user fees by the CVM was to supplement the 
extra manpower that has been increasingly required to handle all the applications that 
the CVM receives.   
 
The Act establishes a fee schedule for FY 2004 through to 2008, including total fees for 
animal drug products, establishments, and sponsors.   
 
Each category is expected to generate 25 per cent of the required revenue, each year.  
The CVM expects to generate the following revenue once ADUFA has been 
implemented: 
 
  FY 2004:    $5M 
o  Drug Application Fees:  $1.25M (25%) (Includes New Animal Drug 
Applications and Supplementary Animal Drug Applications) 
o  Establishment Fees:  $1.25M (25%) 
o  Sponsor Fees:  $1.25M (25%) 
o  Product Fees:  $1.25M (25%) 
  FY 2005:    $8M 
  FY 2006-2008:  $10M 
 
To provide the CVM with revenue predictability, 75% of the fees will be collected at the 
beginning of the year as product, establishment and sponsor fees.  The remaining 25% 
will be collected as application fees at the time of submission. 
 
The applicant will still be responsible for funding all the clinical and field tests required to 
submit their product to the CVM. 
 
As mentioned above, ADUFA sets out certain revenue goals, beginning in FY2004 and 
ending in FY2008.  As of January 14, 2004, the specifics of the fee make-up had not yet 
been published under the Federal Register, but the Animal Health Institute has provided 
a preliminary overview of the fees (refer to Table 2.1).   
 
According to this animal drug user fee program, the majority of the revenue generated 
by fees will come from drug application fees, particularly new animal drug applications.  
In FY2004, the average expected NADA fee is $35,370, rising to $71,500 by FY2006.  
Sponsor fees and supplementary new animal drug (sNADA) fees are expected to start 
between $17,600 and $17,850 in FY2004 and increase to between $35,200 and 
$35,700 by FY2006.   
 The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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Table 2.1  US Animal Drug User Fee Program 
 






      






























* Canadian amount based on April 9, 2003 Bank of Canada Exchange Rate: 0.8814 (1.1346) (Bank of 
Canada, 2003). 




In addition to providing funding for the agency, the legislation will impose performance 
standards (on the agency) that are expected to improve the drug approval process.  
Performance goals were set out for the CVM under ADUFA.  The five-year goals (to be 
implemented by September 30, 2008) are as follows: 
 
•  Review and act on 90 percent of: 
o  Complete animal drug applications (NADAs) and reactivations of such 
applications within 180 days after submission date. 
o  Non-manufacturing supplemental animal drug applications (i.e., 
supplemental animal drug applications for which safety or effectiveness 
data are required) and reactivations of such supplemental applications 
within 180 days after submission date. 
o  Manufacturing supplemental animal drug applications and reactivations of 
such supplemental applications within 120 days after submissions date. 
o  Investigational animal drug study submissions within 180 days after 
submission date. 
o  Investigational animal drug submissions consisting of protocols, that the 
Agency and the sponsor consider to be an essential part of the basis for 
making the decision to approve or not approve an animal drug application 
or supplemental animal drug applications, without substantial data within 
50 days after submission date. 
o  Administrative animal drug applications (NADAs submitted after all 
scientific decisions have been made in the investigational animal drug 
process, i.e., prior to the submission of the NADA) within 60 days after the The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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submission date. 
Source:  USFDA/CVM ADUFA Website, 2004 
 
These goals are further detailed in the table below.  The goal for original and reactivated 
NADAs, is to reduce the review time from 295 days in FY2004 to 180 days by FY2008, 
and to be on time 90% of the time.   Similarly, for supplemental NADAs and reactivated 
supplements, the target is to reduce the review time to 180 days by FY2008, from 320 
days today. 
 
Table 2.2  ADUFA Performance Standards  
 
Goal %  on  time  FY1  FY2  FY3  FY4  FY5 
            
Original and 
reactivated NADAs 
90% 295d  270d  230d  200d  180d 






90% 320d  285d  235d  200d  180d 





90% 225d  190d  140d  120d  120d 
            
Administrative 
NADAs 
90% 90d  85d 80d 70d  60d 
            
INAD studies with 
Data 
90% 320d  285d  235d  200d  180d 
            
INAD Protocols 
without Data 
90% 125d  100d 80d  60d 50d 
            
Fees   $5MM  $8MM  $10MM  $10MM  $10MM
Source:  USFDA/CVM ADUFA Website, 2004 
 
These performance standards choose predictability over timelines.  Slightly longer 
timelines are expected in order to have a 90% predictability of meeting the timeframes.  
One of the key reasons for this, is that industry has indicated it is critical that statutory 
timeframes be met by the fifth year. 
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A review of CVM review times for FY2002 was undertaken by the Animal Health 
Institute (AHI).  The cumulative results for all divisions of the CVM are shown in the 
table below. 
 
Table 2.3 – Animal Health Institute Survey of CVM Review Times for FY2002 
 
Cumulative Results (All Divisions) 








Time of Overdue 
Review in Days 
Longest 
Elapsed Time in 
Days 
Protocol with no data 
(50 days) 
40 89  69%  100  314 
Protocol with data (100 
days) 
2 4  67% 207  252 
Study with minor data 
(100 days) 
10 11  52%  192  622 
Study with substantial 
data (180 days) 
25 37  60%  385  1174 
Phased technical 
section (180 days) 
34 56  62%  361  1193 
Original NADA (180 
days) 
1 5  83% 352  562 
Administrative NADA 
(45 days) 
2 4  67% 148  180 
Supplemental NADA 
(180 days) 
64 68  52%  338  1113 
Reactivation of an 
original NADA (180 
days) 
1 3  75% 378  695 
Amendment to Original 
NADA (180 days) 








22 14  39%  291  480 
Amendment to 
reactivation (180 days) 
0 0   n/a  n/a 
Amendment to 
reactivation of a 
Supplement (180 
days) 
0 0   n/a  n/a 
505 Total 
Submissions 
209 296  59%     
Source:  AHI, 2002. 
 
For the 2002 fiscal year, the CVM 180 day standard was overdue 83% of the time for an 
original New Animal Drug Application (NADA).  Note that this is an improvement from 
the 90% overdue rate in 2001 (original NADA’s).  The longest elapsed time to complete 
an approval in this category was 562 days (862 days in 2001 (AHI, FY2001)).  In the The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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supplemental NADA – the category with the most submissions – the CVM 180 day 
standard was overdue 52% of the time, with the longest elapsed time to complete the 
review at 1113 days (897 days in 2001 (AHI, FY2001)).  Again, this is an improvement 
from FY2001 when CVM was overdue 79% of the time.  It is important to note that the 
CVM had more submissions (total 505) in the 2002 fiscal year; however, there were 







The regulatory system in Australia responsible for agricultural and veterinary chemicals 
is the National Registration Authority for Agricultural and Veterinary Chemicals (NRA).  
It operates a national system that evaluates, registers and regulates agricultural and 
veterinary chemicals.  The NRA must approve any new agricultural and veterinary 
chemical product intended for the market, or any changes to those products already on 
the market.  The NRA also reviews products that have been on the market for many 
years.   
 
In March 2003, the NRA changed its name to the Australian Pesticides and Veterinary 
Medicines Authority (APMVA) in an attempt to more clearly identify the organization’s 
role and area of focus.  The APMVA name will be used in all public communications, 
however, all decisions and formal processes will continue under the name of the NRA 
until the legislative amendment comes into effect. 
 
Prior to March 1995, the Commonwealth held responsibility for the evaluation and 
assessment of selected agvet chemical products and their clearance for registration. 
The States and Territories were responsible for the registration and control of use of all 
agvet chemical products. 
 
In July 1991, the Commonwealth, States and Territories agreed to establish the 
National Registration Scheme (NRS) for agricultural and veterinary chemicals. The 
development of the NRS sought to place under one national umbrella the assessment 
and registration of all agvet chemical products previously undertaken independently by 
the Commonwealth and each of the States and Territories. 
 
The NRA was established in 1993 as a Commonwealth Statutory Authority, with 
responsibility for the evaluation, registration and review of agricultural and veterinary 
chemicals, and their control up to the point of retail sale. The States and Territories 
retain responsibility for control-of-use activities, such as licensing of pest control 
operators and aerial spraying. 
 
                                            
5 In FY2002 there were a total of 6 original NADA and 132 supplemental NADA submissions.  In FY2001 
there were a total of 10 original NADA and 142 supplemental NADA submissions. 
6 NRA, 2003 The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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An overall focus for the NRA has been to establish openness and transparency in the 
decision-making process.    When there are new chemical products, or major 
extensions of product use being assessed, public opinion is sought before the final 
decisions on registration are made.  Initiatives such as the Existing Chemicals Review 
Program are developed with the benefit of community and industry consultation. 
Structure of the NRA 
 
The NRA falls within the Ministry of Agriculture, Fisheries and Forestry.  It employs 
approximately 120 people and is managed by a Chief Executive Officer who is 
responsible for the Board of Directors. 
 
The NRA’s board is comprised of one part-time Chair and eight part-time Directors, 
selected for their expertise in policy development, agricultural and veterinary chemicals 
regulation, the agricultural and veterinary chemicals industry, the rural sector, 
occupational health and safety and consumer interests.   
 
Consultations and communication are high priorities in the NRA and to emphasize this 
they set up three committees that allow participation in the decision making process at 
the industry, state and community levels.   The Registration Liaison Committee operates 
at the state level and provides a mechanism for the States and Territories to co-ordinate 
their functions and responsibilities.  The Industry Liaison Committee meets to discuss 
fees for the cost recovery program and management issues as they affect the NRA’s 
customers.  Finally, the Community Consultative Committee offers community advice on 
registration and public information issues.   
 
Legislation Governing the NRA
7  
 
The NRA was established on June 15 1993 under the Agricultural and Veterinary 
Chemicals (Administration) Act 1992.  The NRA is an independent statutory authority. It 
implements the legislative powers and functions provided to it under the legislation on 
behalf of all jurisdictions. It has responsibility, in particular, for the implementation of the 
Agvet Codes. 
 
Legislation regarding the National Registration Scheme consists of seven acts: three 
dealing with registration activities and four dealing with registration fees and charges.   
The Agricultural and Veterinary Chemicals Code (the 'Agvet Code') scheduled to the 
Agricultural and Veterinary Chemicals Code Act 1994, contains the detailed operational 
provisions for registering chemical products and provides the NRA with its full range of 
powers, including the evaluation, registration and review of agricultural and veterinary 
chemical products (including active constituents and product labels); the issuing of 
permits; the control of the manufacture of chemical products; controls regulating the 
supply of chemical products; and provisions ensuring compliance with, and for the 
enforcement of the Code. The last four Acts in the package contain the cost recovery 
                                            
7 NRA Website, Legislation Governing the NRA  The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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mechanisms - in particular, the imposition, assessment and collection of a levy on sales 
of chemical products - which establish the NRA as an independent, self-funding 
regulatory body. 
 
The Agvet Code is a law of the Commonwealth that only applies in the Australian 
Capital Territory. To enable the Agvet Code to have national coverage, each of the 
States and the Northern Territory enacted complementary legislation that has the effect 
that the Agvet Code of the Australian Capital Territory is applied as a law of each State 




Agricultural and Veterinary Chemicals (Administration) Act 1992 [No. 262 of 1992] 
http://www.nra.gov.au/publications/nrafact200.pdf 
 
This Act, which came into effect on 15 June 1993, establishes the NRA as a statutory 
authority. The NRS is a partnership between the Commonwealth and the 
States/Territories under which the NRA was established as a Commonwealth Statutory 
Authority, with responsibility for the evaluation, registration and review of agricultural 
and veterinary chemicals, and their control up to the point of retail sale. The States and 
Territories retain responsibility for control-of-use activities, such as licensing of pest 
control operators and aerial spraying. 
 
Agricultural and Veterinary Chemicals Act 1994 [No. 36 of 1994] 
http://www.nra.gov.au/about_us/AgVetChemAct94.rtf 
 
This Act, which was part of the National Registration legislation and thus commenced 
on 15 March 1995, contains the constitutional and other legal provisions that enable the 
Agvet Code to have effect. The essence of the legislative arrangements that give effect 
to the NRS is, by means of complementary adoptive legislation, for the Commonwealth 
Parliament to pass a law establishing the Agvet Code in the Australian Capital Territory. 
This Act does this. The Agvet Code then is applied by the legislatures of the States and 
the Northern Territory as a law of those jurisdictions by state/territory complementary 
Acts - the Agricultural and Veterinary Chemicals [State/Northern Territory] Acts 1994. 
This federal Act also contains the Commonwealth provisions that partly 'federalised' the 
applied Agvet Codes. This 'federalisation' of the applied laws was explained in the 
earlier part of this Appendix. This Act also repealed the Agricultural and Veterinary 
Chemicals Act 1988. 
 
Agricultural and Veterinary Chemicals Code Act 1994 [No. 47 of 1994] 
http://www.nra.gov.au/about_us/AgrVetChemCode94.rtf 
 
This Act, which was part of the National Registration legislation and thus commenced 
on 15 March 1995, contains as a schedule the Act, the 'Agvet Code', which has the 
detailed provisions allowing the NRA to evaluate, approve or register, and review active The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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constituents and agricultural and veterinary chemical products (and their associated 
labels); to licence the manufacture of chemical products; and to issue permits. The 
Agvet Code also contains detailed offence provisions allowing the NRA to regulate the 
control of agvet chemicals and it has other provisions for ensuring compliance with, and 
enforcement of, the Agvet Code. As well, the Code contains provisions for data 
protection compensation for review data. 
 
The Assessment Process 
 
Before applying to register a new agricultural or veterinary chemical product, it is 
expected that companies undertake extensive product development, testing and field 
trials to generate data to justify registration of the product and to meet the standards 
required by the NRA assessment process.   The amount of time it takes to complete the 
necessary field trials varies depending on the complexity of the product, but rough 
estimates indicate that it takes five years plus.   
 
When an application is received, the NRA undertakes a detailed, independent 
assessment of all the data to ensure it meets the high standards of quality, safety and 
efficacy and that the product will not have an unacceptable adverse effect on public 
health.   Residue studies on food-producing crops and animals are performed to 
establish a Maximum Residue Limit (MRL) and withholding period (WHP). 
 
Specialist advice during the assessment process comes from three Commonwealth 
agencies:  the Chemicals and Non-Prescription Drugs Branch, Environment Australia 
and The National Occupational Health and Safety Commission. 
 
Figure 2.1 summarizes the registration process for agricultural and veterinary 
chemicals.  
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Figure 2.1  Summary of the Australian Registration Process for Agricultural and  
  Veterinary  Chemicals 
 
 
Source:  NRA Facts, 1999 The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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Following assessment, the product may be registered or rejected.  In many cases, the 
NRA proposes amendments to the product label as a requirement of registration.    
Depending on the product, this process may take months, or even a year or more to 
complete.  It depends on the type of product and the nature of the testing involved.   
 
Each year the NRA registers between 30 and 40 new agricultural and veterinary active 
constituents and approximately 1000 new products based on existing active 
constituents.  In addition, approximately 1300 applications to vary existing products, 
ranging from repacks of currently registered products through to major variations in 
formulation, are registered each year.   
 
The next section discusses the fee scheme and the assessment time-frame in more 
detail. 
 
Fee Scheme and Assessment Timeframe 
 
The NRA recovers most of its operational costs through fees and levies paid by the 
agvet chemicals industry.  These are recovered through: 
•  Application fees; 
•  Annual registration renewal fees; and  
•  Levies on disposals of registered products. 
 
Application Fees:  imposed under the authority of the Agricultural and Veterinary 
Chemicals Code (scheduled to the Agricultural and Veterinary Chemicals Code Act 
1994).  They vary according to the type of application and the assessment required.  
Registration applications are assessed as soon as the necessary data is presented and 
the appropriate fee is paid.  Companies can apply for a partial rebate of the application 
fee paid if the timeframe for approval is exceeded.  
 
Registration Renewal Fees:  good for one financial year and are based on the product’s 
disposals for the previous calendar year.  The term disposal refers to Australian 
products sold, used or given away in Australia by the manufacturer; and 
imported products sold, used or given away in Australia by the importer. 
 
Levies:  the NRA imposes levies on disposals of registered agvet chemical products 
through three Acts: the Agricultural and Veterinary Chemical Products Levy Imposition 
(General) Act 1994, Agricultural and Veterinary Chemical Products Levy Imposition 
(Excise) Act 1994, Agricultural and Veterinary Chemical Products Levy Imposition 
(Customs) Act 1994. 
 
The following table outlines the typical fees and assessment periods that various 
applications undergo in the assessment process, as mandated under the authority of 
the NRA. 
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Table 2.4  Australian Fees and Assessment Periods for New Products 
 
Fees and Assessment Periods – New Products 
Description 
Assessment 
Period (mths)  Fee  
New Active - Primary Application  15 
$              20,260 
*(17,857 CAD)
New Active - Secondary Application  15 
 $                2,060 
(1,815 CAD)
New Combination, approved actives - 
primary application  8 
$              12,370 
(10,900 CAD)
New combination, approved actives - 
secondary application  8 
 $                1,030 
(908 CAD)
New Product, approved active - new 
situation 8 
 $              12,370  
(10,900 CAD)
Repack 3 
 $                   620 
(546 CAD)
Major Formulation Change  3 
 $              12,370  
(10,900 CAD)
Fees and Assessment Period - Variations to Registered Products 
Major Extension  8   $              10,310  
Minor Extension  5 
 $                2,060 
(1,815 CAD)
Minor Formulation Change  3 
 $                1,030  
(908 CAD)
Administrative Label Change  3 
 $                   620 
(546 CAD)
Technical Label Change  8 
 $                2,060  
(1,815 CAD)




Period (mths)  Fee 
1.Application  No set period 
 $                   620 
(546 CAD)
2. Chemistry Assessment  5 
 $                1,030  
(908 CAD)
3. Toxicology (full package)  15 
 $                9,690 
(8,540 CAD)
4. Toxicology (partial package)  12 
 $                5,980  
(5,270 CAD)
5. Toxicology (acute studies only)  8 
 $                2,475  
(2,181 CAD)
6. Residues Assessment  8 
 $                2,475  
(2,181 CAD)
7. Occupational Health and Safety 
Assessment 5 
 $                1,030  
(908 CAD)The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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8. Environmental Assessment  12 
 $                3,095  
(2,728 CAD)
9. Efficacy Review - Category One  6 
 $                3,095  
(2,728 CAD)
10. Efficacy Review - Category Two  5 
 $                2,060  
(1,815 CAD)
11. Efficacy Review - Category Three  5 
 $                1,030 
(908 CAD)
12. Minor Use - requiring one or more 
MRL's 8 
 $                   620 
(546 CAD)
13. Any other Assessment  5 
 $                   620  
(546 CAD)
1 Applications not fitting into the new products or variations to products category are 
assessed under the modular category.  In addition, where a submission contains several 
applications it will be assessed under the modular fees list. 
* Canadian amount based on April 9, 2003 Bank of Canada Exchange Rate: 
0.8814 (1.1346) (Bank of Canada, 2003). 
Source:  NRA, 2003 
 
Legislation governing the NRA allows for 15 months for the worst-case category of an 
application (or more if there are major deficiencies in the application) for new active 
constituent products (refer to Appendix A for an assessment timeline of new drug 
submissions).  Shorter timeframes are allowed for less complex applications (e.g., new 
use for already registered product).  This allows time for screening an application, 
consultation where necessary, and hands-on evaluation of the data submitted.  There 
are two stages in the registration process: administration screening to ensure that the 
application is complete and properly prepared, and technical evaluation. 
 
Possible delays in the registration of a product may result from: 
 
•  Insufficient data supplied; 
•  Application fee not included;  
•  Labels not prepared according to the relevant labelling code; and  
•  Applications submitted without necessary letters for support. 
 
Appeals Procedure 
Applicants have the right to obtain a formal written statement from the NRA setting out 
the findings of an evaluation, with references to the materials on which those finding 
were based and reasons for the NRA's decision. Applications must be in writing and 
should be lodged with the NRA Corporate Secretary within 28 days of a decision. 
An applicant may apply, in writing, for the NRA to reconsider a decision under section 
166 of the Agvet Code. Following reconsideration, the NRA may either confirm, set 
aside or vary its decision. 
In addition, under section 167 of the Agvet Code, the Administrative Appeals Tribunal 
(AAT), subject to the Administrative Appeals Tribunal Act 1975, can review the decision The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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of the NRA to vary the conditions of a registration and to approve a label. An application 
to the AAT must be in writing, accompanied by the required filing fee and be lodged 




According to an NRA spokesperson
8, the NRA meets their legislative timeframes 97-
98% of the time.  The 2001-02 Annual Report for the National Registration Authority for 
Agricultural and Veterinary Chemicals gives an overview of how the system performed 
in the 2001-02 period (NRA, 2002).  Of the 2,529 applications for registration, variation 
of registration or label approval finalized in the 2001-02 period, 96.2% were completed 
within the NRA’s statutory timeframes.   The following table analyzes veterinary 
registrations approved in the 2001-02 period according to their class of application and 
the amount of time it took for the product to be approved or finalized. 
 
Table 2.5  NRA Veterinary Registrations in 2001-02 
 







<100% 100-120% >120% 
Average 







15 Month  16  11 3 2 12.5  26.6
13 Month  3  3 0 0 11.5  43.3
12 Month  1  1 0 0 10.6  36.4
8 Month  56  54 2 0 6.2  15.9
5 Month  122  115 5 2 3.5  9.7
3 Month  830  825 1 4 0.7  3.7
Total 1028  1009  (98.1%) 11 8     
NRA Annual Report, 2002 
 
The above table illustrates that the NRA often meets their statutory timeframe and in all 
cases the average clock time required to finalise a submission was below the statutory 
timeframe.  As noted above, companies can apply for a partial rebate of the application 
fee if the timeframe is exceeded.  
 
A review of the NRA system drew the following conclusions about the registration of 
Agvet chemical products that are safe and effective for their intended use and satisfy 
requirements for safety to people, animals, the environment and trade: 
                                            
8 A note on Australia’s registration system in comparison with Canada and other countries from Peter 
Raphael at the NRA: “Australia has participated in an international benchmarking study of pesticide 
registration conducted by consultants.  Canada also participated and it’s possible that the PMRA may let 
the George Morris Centre have access to the report.  There have been several independent Australian 
reviews that have concluded that the NRA is at ‘world’s best practice’.  Companies with worldwide 
experience usually do not complain about the Australian system with much conviction and acknowledge 
that <the Australian system> is both cheaper and quicker than comparable countries”.    The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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•  There was improved industry compliance with registration requirements due to better 
information and feedback; 
•  Decisions about active constituents and chemical products were made within 
statutory framework; 
•  Registered products in the marketplace meet legislative requirements for 
performance and safety due to sound decision-making. 
 
 
2.3 European  Union
9 
 
The registration of veterinary drug products in the European Union falls under the 
authority of the European Medical Evaluation Agency (EMEA).  The EMEA is in charge 
of co-ordinating scientific resources existing in Member States
10 with a view to 
evaluating and supervising medicinal products for both human and veterinary use.  On 
the basis of the Agency’s opinion, the European Commission authorizes the marketing 
of innovative products and arbitrates between Member States for other medicinal 
products in the case of disagreement.  
  
The EMEA was established in July 1993 by Council Regulation (EEC) 2309/93, which 
lays down the community procedures for the authorization and supervision of medicinal 
products for human and veterinary use and establishes a European agency for the 
evaluation of medicinal products
11 (Official Journal L214, 24/08/1993, p.0001-0021). 
 
Structure and Responsibility 
 
The Agency is comprised of: 
 
•  A management board which consists of two representatives per Member State, two 
representatives of the Commission, and two representatives appointed by the 
European Parliament. 
•  Three committees responsible for preparing the Agency’s opinion on questions 
relating to medicinal products for human use (CPMP – Committee for Proprietary 
Medicinal Products), for veterinary use (CVMP) and for the designation of ‘orphan 
drugs’ for rare diseases.  The CVMP consists of two members nominated by each 
Member state. 
•  An executive director. 
•  A secretariat. 
 
The Council Regulation (EEC) 2309/93 sets out the core tasks of the EMEA as: 
                                            
9 EMEA, 2003 
10 The Member States includes the 15 Member Countries of the European Union (United Kingdom, 
Ireland, Germany, Austria, Spain, Portugal, Italy, Greece, Netherlands, Sweden, France, Belgium, 
Luxembourg, Denmark and Finland) as well as the European Free Trade Association states (Norway, 
Iceland and Liechtenstein). 
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•  The scientific evaluation of quality, safety, efficacy of medicinal products for human 
and veterinary use. 
•  The assessment reports, summaries of products characteristics, labels and package 
inserts. 
•  The supervision of medicinal products (pharmacovigilance).  
•  Providing scientific opinions regarding MRLs. 
•  Ensuring compliance with good manufacturing practice, good laboratory practice and 
good clinical practice. 
•  Facilitating cooperation between Member States, the Community and international 
organizations and third world countries. 
•  Reviewing the status of marketing authorizations. 
•  Advising companies on the conduct of various tests and trials. 
 
Gaining Marketing Authorization through EMEA 
 
A veterinary product may only be placed on the market in the European Union when a 
marketing authorization has been issued by the competent authority of a Member State 
for its own territory (national authorization), or when authorization has been granted in 





The competent authorities of the Member States are responsible for the granting of 
marketing authorizations for medicinal products which are placed on their markets, 
except for medicinal products which are authorized under Regulation (EEC) No 2309/93 
(Community Authorizations, see below).  
 
In order to obtain a national marketing authorization, an application must be submitted 
to the competent authority of the Member State.   For the majority of conventional 
medicinal products, a decentralized procedure exists and is based on the principle of 
mutual recognition of national authorizations.  It provides for the extension of marketing 
authorizations granted by one Member State to one or more Member States as 
identified by the applicant.  When the original national authorization cannot be 
recognized, the points in dispute are submitted to the EMEA  for arbitration.  The opinion 




The Community is responsible for the granting of marketing authorizations for medicinal 
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•  Developed by means of one of the biotechnological processes referred to in 
Regulation (EEC) No 2309/93, Annex, Part A
12, which may only be authorized by a 
Community authorization following an evaluation according to the centralized 
procedure; 
•  Medicinal products referred to in Regulation (EEC) No 2309/93, Annex, Part B
13, for 
which the applicant has chosen the centralized procedure leading to a Community 
authorization. 
 
In order to obtain a Community authorization, an application must be submitted to the 
EMEA. 
 
The scientific evaluation of the application is carried out within the Committee for 
Veterinary Medicinal Products (CVMP) of the EMEA, and a scientific opinion is 
prepared. The opinion is sent to the European Commission, which drafts a Decision. 
Having consulted through the relevant Standing Committee, normally the Commission 
adopts the Decision and grants a marketing authorization. 
 
Such a marketing authorization is valid throughout the Community and confers the 
same rights and obligations in each of the Member States as a marketing authorization 
granted by that Member State. 
 
                                            
12 Part A Products:  Veterinary medicinal products including those not derived from biotechnology, 
intended primarily for use as a performance enhancer in order to promote the growth of treated animals 
or to increase yields from treated animals. 
 
Any veterinary medicinal product in the composition of which there is a proteinaceous constituent 
obtained by means of a biotechnology process, falls under the scope of Part A, irrespective of whether or 
not the constituent is an active substance of the veterinary medicinal product. This also applies where a 
biotechnology manufacturing step is introduced into the manufacture of a proteinaceous product after the 
granting of a marketing authorization. 
 
Examples of new biotechnology products which would be considered obligatory for the Centralized 
Procedure are given below: 
•  Product intended for gene therapy;  
•  Vaccines from strains developed by means of recombinant DNA technology, including gene 
deletion;  
•  Any veterinary medicinal product for which a monoclonal antibody is used at any stage in the 
manufacturing process;  
•  Cell therapy products, which are the result of any biotech process referred to in Part A of the 
Annex to Regulation (EEC) No 2309/93 
13 Part B products - applicants may use the Centralized Community procedure at their own discretion. 
Includes medicinal products intended for use in animals containing a new active substance which, on the 
date of entry into force of Council Regulation (ECC) No 2309/93, as amended, was not authorized by a 
Member state for use in a medicinal product intended for use in animals. 
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Application Procedure 
 
Pre-Submission - The EMEA emphasizes the importance of pre-submission meetings 
with applicants.  These meetings should take place 4-6 months prior to the anticipated 
date of submission of the application.  These meetings are a vital opportunity for the 
applicant to obtain procedural, regulatory and legal advice from the EMEA.  This 
process helps applicants submit applications that are in conformity with the legal and 




Table 2.6 illustrates the fee structure used by the EMEA, under the authorization of the 
Council Regulation (EC) No 2743/98 of December 14, 1998. 
 
Table 2.6  EMEA Fee Structure 
 
EMEA Fee Structure 





For a single strength associated with a 
pharmaceutical form 
Additional Fee 
 +10,000 Euro 
(15,683 CAD) 
For each additional strength and or 
pharmaceutical form submitted at the time 
of initial application 
  
 + 5,000 Euro 
(7,841 CAD) 
For each additional presentation of the 
same strength and pharmaceutical form 
submitted at time of initial application 




For a single strength associated with a 
pharmaceutical form 
Additional Fee 
 + 5,000 Euro 
(7,841 CAD) 
For each additional strength and or 
pharmaceutical form and or presentation 





For a single strength associated with a 
pharmaceutical form 
Additional Fee 
 +10,000 Euro 
(15,683 CAD) 
For each additional strength and or 
pharmaceutical form submitted at the time 
of initial application 
  
 + 5,000 Euro 
(7,841 CAD) 
For each additional presentation of the 
same strength and pharmaceutical form 
submitted at time of initial application 




For a single strength associated with a 
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Additional Fee 
 + 5,000 Euro 
(7,841 CAD) 
 
For each additional strength and or 
pharmaceutical form and or presentation 





For a new strength; a new pharmaceutical 
form; a new target species; a new 




For a new presentation of an already 
authorised strength, pharmaceutical form 
or route of administration 




For a new strength; a new pharmaceutical 
form; a new target species; a new 
indication; a new route of administration 









For any inspection within or outside of the 
EU 




Covering all authorised presentations of a 
given medicinal product 
Scientific Advice Fee     
  
up to 30,000 Euro 
(47,049 CAD) 
Request of scientific or technical advice 
concerning research and development, to 
lead to an application for a marketing 
authorisation or extension of an existing 
marketing authorisation 
Maximum Residue Limits 
Establishment of MRL 
50,000 Euro 
(78,415 CAD) 
Fee will be deducted from the fee for an 
application of a marketing authorisation or 
for an extension of the medicinal product 
containing the substance subject to the 
MRL and submitted by the same applicant
* Canadian amounts based on the April 9, 2003 Bank of Canada Exchange Rate: 1.5683 (0.6376) 
Source:  EMEA, 1999 
 
The following is a list of definitions to accompany Table 2.3 (EMEA, 1999). 
Strength  
•  For single-dose preparations, total use, the strength is defined as amount of 
active substance per unit of dose. 
•  For single-dose preparations, partial use, the strength is defined as the 
concentration expressed in the amount of active substance per ml, per puff, 
per drop, per kg in percentage as appropriate. The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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•  For multi-dose preparations, the strength is defined as the concentration 
expressed as the amount of active substance per ml, per puff, per drop, per 
kg, as appropriate. 
 
•  For powder for reconstitution (powder for oral solution or suspension, powder 
for solution for injection, etc.) the strength is defined as the concentration after 
dissolution or suspension (reconstitution) to the volume and liquid 
recommended.  
 
•  For concentrates for solutions (for injection or for infusion) the strength is 
defined as the concentration of the concentrate before dilution.  
Pharmaceutical Form:  According to full terms in the “Standard Terms” published by the 
Council of Europe. 
Presentation:  Each unit/entity of a certain strength and form of a pharmaceutical 




The maximum timeframe for a marketing authorization application under the Centralized 
Community Procedure is 210 days (does not include pre-submission meeting 90 days 
prior to the official start date), excluding clock stops when additional written or oral 
information is required by the CVMP with regards to a response to a question asked by 
the CVMP (refer to Appendix B for an assessment timeline of new drug submissions). 
 
The EMEA will send the applicant an acknowledgement of the receipt of a dossier and, 
within 10 working days following the receipt, will complete its validation.  At the end of 
the validation process the EMEA will start the procedure.  If within a month from the 
start of the procedure any other member of the CVMP has not received the requested 
parts of the dossier from the applicant, they will stop the clock.   
 
The following table (2.7) is the complete EMEA evaluation process by days and action. 
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Table 2.7  EMEA Evaluation Timeframe 
Day Action 
-90 Pre-submission  Meeting 
1 Start  the  procedure 
70  Receipt of the Assessment Report from the Rapporteur by 
the co-Rapporteur, the CVMP members and the EMEA 
Secretariat.  Rapporteur’s.  Assessment report is also sent to 
the applicant without confidential aspects by the EMEA 
Secretariat. 
85  Receipt of the Co-Rapporteur’s critique of the Rapporteur’s 
Assessment report by the Rapporteur, CVMP members and 
the EMEA secretariat.  The Co-Rapporteur’s critique is also 
sent to the applicant 
100  Comments from members of the CVMP 
115  Receipt of draft list of questions (including overall 
conclusions and overview of the scientific data) from (Co-) 
Rapporteur by CVMP members and EMEA.   
120  CVMP adopts the list of questions as well as the overall 
conclusions and overview of the scientific data to be sent to 
the applicant by the EMEA.  Clock Stop 
121  Submission of the response, restart of the clock (on 11 
official dates per year).  Submission of all 11 updated 
language versions of the summary of product characteristics 
(SPC), labelling and Package insert. 
150  Common Response Assessment Report.  
150-190  Review of all translations of the SPC, labelling and package 
insert by the Quality Review of Documents group.  
Comments also sent to applicant. 
170  Deadline for comments from CVMP Members. 
180  CVMP discussion and decision on the need for an oral 
explanation by the applicant.  If needed, clock is stopped 
while applicant prepares for discussion. 
181  Restart of the clock and oral explanation. 
195  Final draft of English version of SPC, labelling and package 
inserts by applicant. 
By 210  CVMP opinion + CVMP draft Assessment Report. 
BY 215 at latest  Applicant provides CVMP and EMEA members with all 
translations of SPC, labelling and package inserts. 
225  Applicant prepares final revised translations of SPC, 
labelling and package inserts. 
240  Transmission of opinion to applicant, Commission and 
Member States in all languages. 
By 300  Finalization of EPAR in consultation with applicant (for 
confidentiality purposes)  Source:  EMEA, 1995-2004 The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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Appeals Procedure 




The 2001 Seventh Annual Report (EMEA, 2001) of the EMEA provides information on 
how the system performed in 2001.  In 2001, the EMEA received 9 applications for new 
and innovative products which fall under Part A and Part B of the Annex to Council 
Regulation (EEC) 2309/93, compared to 6 applications in 2000 and 4 applications in 
1999.  The target range for applications is 10.   
 
The average number of calendar days required to finalise an application in 2001 was 
678 days.  Of this 678 days, 210 days were the assessment phase, 30 days were post-
opinion phase, 94 days were the decision process and 344 days were company stop 
time days.  The average number of days in 2001 to finalise an application is greater 
than 1999 and 2000.  This is mainly attributed to the number of company stop time 
days. 
 
A benchmark study based on the joint EMEA-European Federation of Animal Health 
(FEDESA) questionnaire on the use of the centralized system of authorization was 
completed in 2001 and shows a high level of satisfaction on the part of the European 
veterinary pharmaceutical industry with the centralized system and support for the 
EMEA, reflecting a consistency in full compliance with regulatory deadlines.  The survey 
also found that there was an increase in the number of pre-submission meetings for 
products in 2001 (94%) compared to 2000 (66%). 
 
EMEA has continued to efficiently register and approve new medicinal products. In 2002 
the Committee for Veterinary Medicinal Products (CVMP) at the Agency granted 
authorization for the registration of Draxxin and the active ingredient Tulathromycin 
(EMEA, 2003) submitted by Pfizer Limited. Tulathromycin is intended for the treatment 
of bacterial respiratory disease in cattle and pigs but not intended for use in lactating 
cattle. Pfizer conducted numerous toxicological and pharmokinetic studies prior to 
submitting an application based on the requirements of the CVMP. The drug was 
subsequently approved in a timely fashion. Pfizer initiated the application procedure on 
October 16
th, 2002, and the positive opinion was granted 182 days later, on July 23
rd, 
2003 (EMEA, 2003). In this case, the approval of the drug was faster than the 210-day 
requirement within the EMEA. 
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2.4 The  Canadian
14 Animal Health Product Approval Registration System 
 
The Bureau of Veterinary Drugs (BVD) of Health Canada conducted animal health 
product reviews and approvals in Canada prior to 2001.   The mission statement of the 
BVD stated at that time that, “The Bureau was responsible for evaluating drugs for use 
in animals to ensure that: 
1.  Their use would not leave potentially harmful residues in food products of animal 
origin (meat, milk, eggs fish and honey); 
2.  They were efficacious and safe in the target animal; 
3.  Standards of manufacturing and quality control were acceptable.” 
(Price Waterhouse, 1996) 
 
At the end of 2001, the Veterinary Drugs Directorate was formed from the Bureau of 
Veterinary Drugs.  For the purpose of consistency throughout the document, the Bureau 
of Veterinary Drugs will be referred to as the Veterinary Drugs Directorate, regardless of 
the time period being discussed.  This is particularly important in Section 3, the case 
studies, as many of the companies began the review process with the Bureau of 
Veterinary Drugs. 
 
The Canadian Animal Health Product Approval Registration system for both food animal 
and companion animal drugs is subject to the approval of the Veterinary Drugs 
Directorate of Health Canada.  The Veterinary Biologics Section of the Canadian Food 
Inspection Agency is the regulatory body responsible for the licensing of all vaccines 
and veterinary biologics from manufacturers who wish to sell their products on the 
Canadian market.  The Veterinary Biologics Section has not been reviewed in this 
research.  
 
The Veterinary Drugs Directorate (VDD) 
 
The Veterinary Drugs Directorate (VDD) is part of the Health Products and Food Branch 
of Health Canada. The VDD ensures safety of foods such as milk, meat, eggs, fish and 
honey from animals treated with veterinary drugs. They also ensure that veterinary 
drugs sold in Canada are safe and effective for animals. 
 
Structure and Responsibility 
 
The aim of the VDD is to enhance the efficiency of operations and to streamline the 
review of veterinary drug submissions and experimental studies certificates.  A focus is 
on advancing areas of information management and processing, communications with 
Canadians and working in partnership with stakeholders and addressing a growing 
requirement of regulatory agencies worldwide.  
 
The VDD is headed by a Director General and has six divisions: Human Safety Division, 
Manufacturing and Chemical Evaluation Division, Clinical Evaluation Division, 
                                            
14 Source:  VDD Health Canada Website, 2003 The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
FINAL REPORT     Section 2.0:  Agricultural Product Approval Systems 
 
 
George Morris Centre     31  
Submission and Knowledge Management Division, Strategic Planning and Stakeholder 
Relations Division, and Executive Services.  
 
Within the Clinical Evaluation Division is a Pharmacovigilance Unit.  The strategic focus 
of the Pharmacovigilance Unit is on post-market safety surveillance to improve the 
monitoring of veterinary drugs in Canada. 
 
Approval Process for New Veterinary Drugs 
 
Veterinary drugs are used to prevent and treat diseases in animals caused by micro-
organisms and parasites. Some drugs may help to promote growth, control reproduction 
or provide humane means of restraint and relief of pain in animals.  
 
A new veterinary drug is approved for sale in Canada only if Health Canada is satisfied 
that:  
•  The drug is safe for the animals to be treated and effective for the purpose it is being 
marketed; 
•  It does not leave potentially harmful residues that could pose any health hazard to 
humans eating food products from treated animals (meat, milk, eggs, fish and 
honey); 
•  The drug must be manufactured according to strict specifications and must remain 
stable up to its expiry date.  
 
Review of new veterinary drugs is conducted by the Health Products and Food Branch, 
through the work of the Veterinary Drugs Directorate. 
 
For a new drug to be reviewed, the manufacturer must:  
 
•  Submit a ‘New Drug Submission’ which contains details on manufacturing and 
quality control as well as results of toxicity, pharmacology, residue and clinical 
studies;  
•  Provide the VDD with substantial evidence to support the product's quality, safety 
and efficacy;  
•  Prove that proposed labels for the new drug reflect the data submitted and specify 
adequate directions for use, including withdrawal periods for drugs used in food-
producing animals.    
•  Note that unlike other countries, Canada does not require manufacturers to provide 
information pertaining to non-scientific issues, such as social and economic impacts 
(positive or negative), in their product review. 
 
Manufacturers must also submit information, in a Supplemental New Drug Submission, 
if they wish to make significant manufacturing changes or modify conditions of use 
(labelling) for previously approved drugs.  
If required, the VDD will ask for further information. This process continues until the 
VDD approves or rejects the application.  Scientists in the VDD review the claims and The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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findings of a company in the submissions and ensure that the information that will be 
provided to veterinarians and consumers is clear and unequivocal.  
When there is no clear consensus among its scientists, or when the VDD would benefit 
from outside advice, it may also convene an expert advisory panel to review data and 
recommendations made by scientists.  
 
Following the review of all existing data which could also include an expert panel 
review, the scientists who have evaluated the submission assess the risks and benefits 
and make recommendations to their supervisors to either accept or reject the 
submission. The Head of the Veterinary Drugs Program, taking into account the 
recommendations of the scientists and scientifically trained managers, accepts or 
rejects the submission.  
 
If a submission is accepted and the product is approved, the manufacturer will receive a 
‘Notice of Compliance’ from Health Canada specifying the terms and conditions under 
which the drug can be sold and used. The drug must bear a Drug Identification Number 




The Canadian performance standard for a ‘New Drug Submission’ (includes 
Abbreviated and Supplemental New Drug Submissions) is 180 days (refer to Appendix 
B for an assessment timeline of new drug submissions).  Note that the 180 days to 
reach a decision is an administrative standard, not a performance goal that must be  





Until recently there was no appeal mechanism in Canada during the application process 
or once the drug decisions were made.  In December 2003, a blueprint for appeals was 
published by VDD; however, it is not an independent appeal mechanism as requested 
by industry.   
To serve industry clients more efficiently and enhance transparency, the Veterinary 
Drugs Directorate (VDD) developed a blueprint for the appeal process for veterinary 
drug submissions. The appeal process will be applicable to several VDD procedures 
including VDD's new Submission Management Policy (being developed). The blueprint 
is based on Health Canada's Health Products and Food Branch policy entitled Appeals 
Procedures for Drug Submissions and respects the principles and practices described 
therein (VDD Appeals Website, 2004). 
There will be three levels of appeal, two of which were initiated by industry (not the 
regulator). In each case, the supporting information provided by the industry client will The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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be given due consideration and will be reviewed by scientific evaluators and external 
experts.  
Level One Appeal 
When a manufacturer is dissatisfied with a decision made by VDD that is related to a 
veterinary drug submission, the sponsor now has the right to appeal that decision. The 
manufacturer may contact the Chief or Director of the applicable Division within VDD to 
discuss the disagreement. At that time, VDD will conduct a peer review of the data and 
determine whether the sponsor has provided sufficient data (VVD Appeals Website, 
2004). 
 
Level Two Appeal  
If the industry client does not agree with the decision made in the Level One Appeal and 
wishes to proceed further, an appeal may be made to the Director General of VDD. The 
Director General will review the information, and will consult with VDD's Science Issues 
Review Committee (SIRC). SIRC is comprised of a group of scientific experts and other 
members of the VDD management team (VDD Appeals Website, 2004).  
 
Level Three Appeal  
At the discretion of the Director General and/or the recommendation of SIRC, the 
appeal may be referred for further examination to an external peer review or an ad hoc 
committee. The final decision rests with the Director General of VDD. 
In all appeal requests, a written explanation of the decision will be provided (VDD 
Appeals Website, 2004). 
 






Examples of fees for frequently filed submission types are illustrated in Table 2.8.   
 
                                            
15 The regulations for the fee structure can be found in the Canada Gazette Part II, Volume 130, No. 6, 
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Table 2.8  Examples of Fees for Frequently Filed Submission Types for 
Veterinary Drugs in Canada 
 







CTURING    TOTAL  
NDS: New Entity/Food Species/1000 SF   $     15,980   $ 21,790   $      9,680    $     47,450 
NDS: New Entity/Food Species/100 SF   $     15,980   $ 29,050   $      9,680    $     54,710 
NDS: New Entity/Food Species/100SF/GP   $     31,470   $ 29,050   $      9,680    $     70,200 
NDS: New Entity/Non-Food Species   $     15,980   -    $      9,680    $     25,660 
              
Abbreviated NDS: Food Species   $      2,900   $   2,900   $      9,680    $     15,480 
Abbreviated NDS: Non-Food Species   $      2,900   -    $      9,680    $     12,580 
              
SNDS: Another Food Species   $     15,980   $ 14,520   -    $     30,500 
SNDS: Another Non-Food Species   $     15,980   -    -    $     15,980 
SNDS: New Indication, Same Food Species   $     12,590   -    -    $     12,590 
SNDS: New Indication, Same Non-Food Species  $     12,590   -    -    $     12,590 
              
Concurrent Use in Food Species   $      7,740   $   5,810   $      1,450    $     15,000 
Concurrent Use in Non-Food Species   $      7,740   -    $      1,450    $       9,190 
              
INDS: New Entity/Food Species/Temporary ADI  $      4,840   $ 14,520   $      4,840    $     24,200 
INDS: New Entity/Food Species/1000 SF   $      4,840   $ 21,790   $      4,840    $     31,470 
INDS: New Entity/ Food Species/ 100 SF   $      4,840   $ 29,050   $      4,840    $     38,730 
INDS: New Entity/ Non-Food Species   $      4,840   -    $      4,840    $       9,680 
              
ESC: Food Species/Original  -  -  -   $       2,900 
ESC: Food Species/Repeat  -  -  -   $          480 
ESC: Non-Food Species/Original  -  -  -   $          960 
ESC: Non-Food Species/Repeat  -  -  -   $          480 
              
DIN: Application            $          720 
DIN: Drug Status Information  -  -  -   $          500 
   -  -  -    
Corporate or Drug Name Change  -  -  -   $          250 
              
EDR: Food Species  -  -  -   $          100 
EDR: Non-Food Species  -  -  -   $            50 
              
SF: Safety Factor             
GP: Growth Promotant             
ADI: Acceptable Daily Intake             
             
Source:  VDD (Doing Business with VDD Website), 2003 
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The following is a list of definitions to accompany Table 2.8. 
 
Definitions: 
Schedule 1  New Drug Submission (NDS) 
Schedule II  Supplement to a New Drug Submission (SNDS) 
Schedule III  Abbreviated New Drug Submission and Supplement to and Abbreviated 
New Drug Submission (ANDS, SNDS) 
Schedule IV  Drug Identification Number (DIN) Application 
Schedule V  Preclinical (Investigational) New Drug Submission (INDS) 
Schedule VI  Experimental Studies Certificate 
Schedule VII Emergency Drug Sale (EDR) 
 
Bill C-212, a private members bill (sponsored by Roy Cullen, MP, Etobicoke North), was 
passed unanimously through the House of Commons in September 2003.  The Bill, 
which will likely go to the Senate for consideration in February of 2004, would require 
fee-charging federal departments and agencies to: consult with stakeholders prior to 
establishing a fee; show that a clear private benefit is linked with the fee; establish an 
independent resolution system; and, set performance standards in exchange for the fee 
charged (Business Coalition on Cost Recovery, 2003). 
 
The Bill would also provide fee reductions when performance standards are not met, as 
this has proved useful within the Australian and United States in encouraging fee-




An independent report by Regulatory Data Services (RDS) analysed the market access 
times for veterinary drug products in Canada between 1995 and May 2003
16. 
 
This report found that the average approval times for New Drug Submissions (NDS) 
were increasing from 1996 to 2002.  The average number of days to approval in 1997 
was 402 days, compared to 818 days for 2002.   
 
From 1995 to 2002, the average approval time for NDS was 567 days.  The minimum 
number of days to approval was 116 days and the maximum number of days was 1,828 
days. 
 
The report also found that NDS approval times exceeded the 180-day performance 
standard 87% of the time and that the predictability of NDS approvals is falling.  The 
95% confidence range tended to get broader from 1996 to 2002, with the standard 
deviation at 428 days in 2002 (ranging from 601 to 1035 days).  Marketing decisions for 
a new product get more difficult as the standard deviation gets larger. 
 
                                            
16 Data for this report is collected from the Veterinary Drugs Directorate of Health Canada via the 
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The report indicates that the average approval time for Corporate or Brand name 
changes has shown some improvement, but is still generally above the 90-day 
performance standard.  As well, approval times for Abbreviated New Drug Submissions 
(ANDS) and Supplements to a New Drug Submission (SNDS) have seen upward trends 
with the average approval time in 2002 for ANDS being over 700 days and for SNDS it 
was approximately 574 days (over three times the performance standard). 
 
The conclusions of a comparative study conducted by D.J. Rainnie at the Atlantic 
Veterinary College (Rainnie, 2002) show similar results. Their study compared the 
regulatory requirements of the Centre for Veterinary Medicine (CVM) in the United 
States to VDD with respect to drugs for use in companion animals. Rainnie concluded 
that although the regulatory requirements for both agencies are essentially the same, 
the CVM documents that lay out the requirements are more specific, numerous and 
detailed and therefore are less open to interpretation and resulted in more consistency 
in CVM reviews.  
 
Rainnie’s report also highlighted that the CVM was more formally standardized and less 
flexible in all processes throughout the approval process. Therefore, quality control and 
consistency in the approval process was always higher in CVM when compared to 
VDD.  Rainnie also found that the review process at CVM to be team oriented, but at 
VDD it was more individualistic. Finally, Rainnie found that the interpretation of data 
from the field studies was generally the same in both agencies. This finding should 
encourage more collaboration between the two agencies thereby reducing any 
recreation of field data and reducing the amount of time required during approval 
decision process. 
 
It is important to note that there have been numerous actions taken by the Veterinary 
Drugs Directorate of Health Canada to improve the regulatory process and the time 
required for a decision on new drug submissions.  Like anything, new processes take 
time before the improvements are reflected, for example, in reduced time for drug 
approval decisions and backlog reduction.  Table 2.9 identifies some of the actions 
taken by VDD for improvement in the regulatory process since 2001. 
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Table 2.9  Veterinary Drugs Directorate:  Progress on Key Issues 
 
2001 2002 
27 Employees  80 employees 
No outreach  Education and outreach unit 
No stakeholder relations  Stakeholder committee in place 
No consultations  Consultations – e.g., AMR, MRLs/AMRLs 
No strategic planning  Strategic planning unit operational 
Limited capacity for 
international activities 
VICH – Steering Committee and Working 
Groups, CODEX bilateral activities with 
the CVM 
No IM/IT capacity  Submission and knowledge Management 
Division operational, new Submission 
Management Policy in progress:  E-
review 
No formal adverse drug 
reaction reporting 
Pharmacovigilance unit in place 
Significant submission 
backlog 
Significant submission backlog reduction 
Backlog of corporate 
name changes 
Corporate name change backlog 
eliminated 
37 MRLs  65 AMRLs/MRLs 
  Source:  Kirkpatrick presentation slides at CAHI Annual Meeting, 2003 
 
2.5   Summary 
 
Despite improvements in the Canadian regulatory system, the foregoing reveals several 
issues that remain:   
•  Expense of applications 
o  Canada has a new drug application fee that is among the highest of the 
countries compared, particularly when the size of the Canadian market is 
considered.  
  Canada:  C$25,660-70,200 
  US:  C$30,000-60,500 
  Australia:  C$17,650 
  EU:  C$157,000 for access to 15 member countries 
 
•  The time frame for an approval decision is too long. 
o  The Canadian system makes no commitment with regard to time of 
approval decision and does not adhere to its administrative standards. 
  Canada:  180 days – administrative standard 
  US:  180 days – currently a provisional standard.  The US have 
implemented the Animal Drug User Fee Act (ADUFA) in which the 
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expected to improve the drug approval process to 180 days, 90% of 
the time by 2008. 
  Australia:  240 days 
  EU:  210 working days (does not include clock stop days) 
o  Total elapsed time until a decision made is slowest in Canada, by a wide 
margin.  It is understood that, since the commission of this report, there 
has been effort on the part of the VDD to improve this situation but more 
improvements are needed to make this a world-class regulatory 
environment.  
  Canada: exceeded NDS target 90% of time (2002) 
  US:  exceeded target 83% for NADA (2002) 
  Australia: 96.2% within timeframe (2001-02) 
  EU: no data – last 3 yrs within timeframe 
 
•  Until recently there was no appeal mechanism in Canada during the application 
process or once the drug decisions were made, but they exist in other systems.  
In December 2003, a blueprint for appeals was published by VDD; however, it is 
not an independent appeal mechanism as requested by industry.  
o  There still remains a need for an independent dispute mechanism. 
 
•  There are no mandatory pre-submission meetings (e.g., the EU) for applicants to 
get a better understanding of what is required prior to submission. 
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3.0  The Regulatory Approval System: Case Studies of Past Product Approvals 
 
In Section 2.0, evidence is provided that the approval process in Canada appears to 
present problems for the industry.   Section 3.0 provides evidence of the costs and the 
distribution of costs among market participants created by those problems by 
undertaking a series of case studies.  The section further defines the need for the case 
study analysis, reviews the RIAS model, which was developed to estimate the economic 
impact of regulatory product approval delays by RIAS Inc, and reviews two case studies 
RIAS completed some time ago.  The final section introduces the case study methods 
and the George Morris Centre cases.  
 
3.1  Case Study Analysis 
 
Delays in government regulatory approval cause delays for the introduction of new 
products in markets.  These delays have high costs to businesses and their customers.  
Estimating the empirical real costs of these delays and explaining the costs to 
regulators can be a difficult task.   
 
A measure of the tangible costs associated with the Canadian animal health products 
regulatory system can be made based on the actual experience of firms in the industry 
introducing new products into the Canadian market.  This experience includes the 
evidence that was initially requested by regulators, requests for further evidence and the 
time from approval submission to ruling on approval.  The purpose of the case studies is 
to document these experiences and their associated costs. 
 
3.2  RIAS Inc. Case Study Summary  
 
RIAS Inc. in previous research addressed some of the difficulties identified above.  
Section 3.2 is a summary of two RIAS Inc. case studies (2000), which illustrate the 
economic impact of the regulatory product approval delay in Canada. 
 
The following is an example of lost revenue from a delayed drug approval in Canada.  
The product was a drug designed to be efficacious against a wide variety of parasites in 
dogs and cats.  After submission in Canada, it took 67 weeks to obtain regulatory 
approval.  Recall that the ‘goal’ for veterinary drug approvals in Canada is 180 days.  
Thus, the approval exceeded the goal by 289 calendar days. The same product was 
introduced in the United States eight months before the Canadian approval. As the first 
single entity product against a broad range of parasites, this product was a real 
innovation in its category and was a great success and was widely adopted in the 
United States.   
 
The Canadian regulatory delay cost the company 12% of the value of the drug over five 
years.  That is, the company lost 12% of what it would have earned in Canada if the 
market approval had been within the maximum allowed time.  
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The financial loss due to the regulatory delay was 17% of the total annual Canadian 
sales in animal health products for that firm.  Implications of this loss include fewer new 
products introduced for clinical testing and less employment in the business.   
 
In the synopsis of the RIAS case, they identify that the extreme regulatory delays mean 
many of the company’s new animal health products in use elsewhere will not be made 
available at the same time in Canada. Canadians and their companion animals lose out.  
In addition, consumers are going to the United States and importing the product for their 
use. This is a loss of income for Canadians and inflicts undue hardship on the 
companion animals that are denied the products during the excessive delay.   
 
A second scenario concerns the submission of a growth promotant for livestock.  At the 
time of submission, the product was not approved in the US or European Union and it 
was a unique opportunity for the food production section to gain a production advantage 
in domestic and export markets.  The product took six years to gain approval through 
the Bureau of Veterinary Drugs. Note that the European Union and the US did not 
register the product. Again, the RIAS Inc impact model was used to determine what the 
costs were to the consumer and the Canadian economy.   The company lost 85% of the 
forecast revenue over its first ten years.  Canadian food producers also lost because 
they did not have access to the product for the six years it took to gain approval.  This 
affected Canadian firms by impacting their incentive to develop and market animal 
health products in Canada and as a result research and development took place in 
other countries. 
 
Cleary, there are impacts to the agri-food industry, consumers and the Canadian 
economy from regulatory delays for product approval in Canada.   
 
 
3.3  George Morris Centre Case Studies 
 
Section 3.3 contains a complete description of the case study process, interview results 
and economic impacts for each of the cases analyzed.   
 
For the purpose of consistency throughout the document, the Bureau of Veterinary 
Drugs has been referred to as the Veterinary Drugs Directorate, regardless of the time 
period being discussed.  This is particularly important in this section, as many of the 
companies began the product review process with the Bureau of Veterinary Drugs. 
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3.3.1  Case Study Evaluation 
 
George Morris Centre researchers conducted five case study interviews and analyzed 
the economic impacts to the company and to the agricultural industry as part of this 
research.  The case studies selected were examples of product submissions that were 
delayed in the Health Canada ‘queue’ for approval.  It should be noted that, to date, 
some of the cases analyzed are still pending an approval decision. For this reason, the 
cases are described quite generically in what follows – all companies requested that 
their cases be treated confidentially. 
 
The case studies were selected from among several companies in the Canadian Animal 
Health Institute.  Anonymity of the product and manufacturer is retained throughout this 
report; for identification purposes each case is assigned a verification number, for 
example ‘Case 1’. 
 
A series of questions was developed as a guide for the interviewers (see Appendix A), 
i.e., a structured survey was not used.  Interviews were conducted with staff from animal 
health product firms by George Morris Centre research staff.  
 
Estimating the Economic Impacts 
 
There are three types of loss accounted for when the economic impacts were estimated 
in each of the cases: direct losses, downstream losses and more general impacts to the 
Canadian economy.  Each type is explained in the bullets below
17.   
   
•  Direct Losses to the Company:   
o  The cost of providing additional data and information for Canadian 
regulators; i.e., information/data that were not anticipated or required for 
other jurisdictions’ approvals.   
o  Lost market potential due to the delayed approval decision.  When 
estimating the lost market potential, the net present value
18 was calculated 
from the estimated market losses every year the company waited for 
approval.  In 2003, losses were estimated at present value.  It should be 
noted that these calculations take into account the approval target of 240 
days. Thus, the calculations of potential market losses start 240 days after 
the submission of an approval for each company.  For example, if 
Company X submitted a product for approval in January 2000, potential 
market losses would begin to accumulate in September 2000.   
•  Downstream Losses:   
                                            
17 It should be noted that there were several types of direct costs that we did not calculate as they were 
considered negligible in the big picture. One example is the opportunity cost to the company associated 
with sunk capital.  
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o  Losses to the agriculture industry due to not having the drug available, 
including the potential loss of livestock and/or the loss in productivity. 
 
•  Losses to the Economy:   
o  In some cases the cost of lost opportunities was estimated.  For example, 
a company may have budgeted to hire new personnel specifically related 
to the drug pending approval.  If the company was unable to hire the 
personnel as a result of the approval delays, the job losses were classified 
as an opportunity loss to the economy. 
 
In estimating the economic impacts the following assumptions were made:  
 
•  When estimating the direct loss to companies, foregone sales are used.  Ideally, 
foregone profits would be used, but the cooperating companies did not have 
profit projections.   Profitability of these products could be highly variable, 
depending on whether they require new capital expenditure, and on a host of 
accounting procedures.  For readers who want to think in terms of lost operating 
profits, experience suggests that profits on these types of products would range 
in the area of 7 – 30% of earnings before interest, taxes, depreciation and 
amortization (EBITDA).   
 
•  Each of the products reviewed would eventually receive approval.   
 
•  Industry losses occur when there is a delay in approval beyond 240 days. Note 
that VDD’s administrative review standard is 180-days. However, 240 days was 
selected as a more reasonable expectation of approval.  This review time 
corresponds with Australia’s system, as Australia was shown in the previous 
section to be the fastest and most consistent at reaching their approval targets.   
 
•  The categories of loss described above cannot be added together to determine a 
total economic impact, as it would result in double counting.  Specifically, part of 
the direct losses to manufacturers are measured by lost sales, while the losses 
downstream are measured as lost productivity.  If the two values were added 
together, it would double count the loss because in order for industry to obtain 
the productivity gains they must purchase the product from the manufacturer.  By 
purchasing the product, the manufacturer no longer experiences the loss in 
sales.   
 
To estimate the economic impacts (direct, downstream or economy), compounded net 
present value calculations were used with a 5% discount rate.  Equation 1.0 below 
illustrates the calculation used in this analysis.  The value of X in the equation can be 
interpreted several ways.  For example, it can be interpreted as losses to the company 
(e.g., lost sales), agricultural industry losses (downstream impacts), or losses to the 
economy (for example research opportunities) depending on the calculation being 
analysed. The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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Equation 1.0: 
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Where: 
  TL is the sum of Xn…X4 and estimates the total loss 
  X is the estimated present value of the loss 
  n represents the year the estimated loss would have occurred 
  negative exponent in the denominator represents the number of delayed years 
  X4 is the estimated losses for 2003 (present value). 
 
As an example, suppose a company submitted a new drug submission (NDS) to the 
Veterinary Drugs Directorate in April of 1998.  Based on the application submission date 
and an expected approval time of 240 days (8 months), the company could expect their 
product to be approved and would prepare for market penetration in January of 1999.  If 
approval were not obtained until December 2003, losses would accrue each year the 
company did not receive approval (since 1999).  Using the equation above for our 
example, in 1999 (the first year of losses) the value of lost sales would be represented 
by Xn.  The negative exponent in the denominator would have the value of four, the 
number of years that the losses have been accruing.  The value of X1 is the lost sales 
for the marketing year 2000 and ‘n’ in this case equals negative three.  This process is 
repeated for each of the years, with X4 as the lost sales in 2003 (present value).  The 
sum of each X value equates to the total losses (in present value terms) from not 
obtaining product approval in January 1999.   
 
The following sections summarize the interview discussions and resulting economic 
impacts for the five drug products.  
 
3.3.2  Case Study Results 
 
Three of the five cases conducted by the George Morris Centre are products for the 
commercial livestock industry, while the remaining two are for companion animals.  
Each of the cases is summarized below to provide: 
•  An indication of the length of time until an approval decision was made (or, how 
long to date when a decision has still not been made) 
•  A brief description of the reasons for approval delays  
•  Estimates of the resulting economic impacts (direct, downstream, or impact on 
the economy). 
 
Participating companies are very concerned about confidentiality.  This concern stems 
in part from the normal business desire to not signal competitors about potential new 
products and a desire to maintain a good working relationship with VDD.  For this 
reason, no details are given in the analysis of cases about the products or the dates of The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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application and approval.  In addition, none of the detail of actual events of the 
individual cases is provided.  
 
Length of Approval Delays 
For each of the five cases, significant delays occurred in the amount of time required for 
approval.  The table below illustrates the number of months that elapsed (to date, in 
some cases) beyond the 240 days (8 months) required for approval. 
 
Product  Delay in Approval Time 
1  36 months (1,080 days) 
2  50 months (1,500 days) 
3  134 months (4,020 days) 
4  37 months (1,110 days) 
5  60 months (1,800 days) 
 
Reasons for Approval Delays: 
Throughout the cases, the impacted companies identified a number of reasons for the 
delay in their product approval.  These examples have been listed below in no particular 
order:   
 
  Employee problems within the VDD 
o  In the mid to late 1990’s and in early 2000, delays in product approval 
were linked to a particular employee (reviewed product submissions) 
fighting with the managers.  In addition, there were rotating directors and a 
lack of management guidance within the VDD.  
 
  Lack of communication between divisions and case files.   
o  Information that was required for a submission was available in another 
division of VDD, but was not made available to the reviewer.  The VDD 
reviewer needed to cross-reference information from a previously 
submitted human safety file.  The review was held up as a result of not 
being able to access the human safety file.   
 
  VDD misplaced information/data and required resubmission.   
o  The company was requesting approval for a product that was a new 
formulation of an already approved product.  VDD indicated they lost the 
data from the original approval and that the company would have to 
resubmit it. 
 
  VDD requested additional “new” data and information.   
o  Many companies noted requests for unexpected new data, information or 
further testing.  
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  VDD requested additional research studies not required for approval in 
other countries.   
o  It took 17 months from the original submission for VDD to indicate they 
needed additional efficacy data that would require a major clinical study.  It 
should be noted that this clinical data was available from the clinical trials 
completed in another country, but VDD required a new study to obtain 
Canadian data. 
 
  Emerging antimicrobial resistance (AMR) issues.   
o  As AMR became an emerging issue of concern with consumers and 
government, companies found their product submissions were further 
delayed if their product was classified as an antibiotic.   
 
  VDD re-evaluated research in the submission file that had been previously 
accepted.  
o  Research submitted for the approval had been accepted.  Several years 
later during the review process, additional time was taken by VDD to 
review the research once again. 
 
  Company changed the composition of an inactive ingredient of a 
previously approved drug and VDD required resubmission as a new drug. 
o  Required significant amounts of new data and testing. 
 
  Lack of communication from VDD for extended period of time.   
o  A 36-month period lapsed during which no contact was made from VDD to 
the Company, until an information request was made almost three years 
after the original submission.   
 
These delays among others have resulted in significant economic impacts.  The 
following is a brief description of the direct losses to the companies, downstream 




Company 1 incurred direct costs totalling $21.6 million, which were the result of lost 
potential sales, and facilitation costs.  
 
  The first direct cost resulting from the delay in Product 1’s approval was 
approximately $276,282
19.  These costs were the result of Company 1 having 
additional expenses for consultants over a four-year period to provide advice and 
facilitation to aid in the approval process between Company 1 and VDD.  
Additional internal costs for continued activities with this file have not been 
quantified. 
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  Product 1 was approved in the United States in 1998. As a result, Company 1 
estimated a two-year delay for the product to reach the Canadian market, and 
estimates they have been losing sales since 2000. Company 1 estimated that it 
would capture 15% of this segment of the Canadian market and estimates total 
lost sales of $20 million over the last four years. These losses were estimated at 
$3.8 million, $4.8 million, $5 million, and $6.4 million for each consecutive year 
on the market. The net present value of Company 1’s estimated market losses is 
$21,340,975. 
 
Company 2 estimated a total market potential of $8 million in Canada, of which, 20% 
would be captured in the first year, 30% in the second year, 40% in the third year and 
50% thereafter. The net present value of their estimated market losses was calculated 
at $11.9 million. 
 
Company 3 incurred direct costs totalling $19.5 million, the result of lost potential sales 
and a safety study requested by VDD. 
 
  The first direct cost resulting from the delay in Product 3 approval was 
approximately $90,000.  This represents the value of an additional safety study 
requested by VDD.  
  Company 3 also incurred direct costs totaling $19.4 million, which were the result 
of lost potential sales. In 1992, Company 3 submitted information to VDD 
regarding efficacy and safety testing for Product 3. Company 3 assumed that 
after this submission the approval would proceed as normal and within a 
reasonable approval period (~240 days). Therefore, Company 3 expected to 
begin marketing the product in the later part of 1992, and has incurred lost sales 
since then. Company 3 estimated that Product 3 would have captured 10% of the 
market for the first three years and 17.5% thereafter. Company 3 estimated the 
market for this drug at approximately $9.5 million in Canada, but indicated the 
market shrank to $7 million in 2002. The net present value of Company 3’s 
estimated market losses is $19.4 million.  
 
Estimating the direct losses for Company 3 is a precarious situation because there were 
six years where the company did not actively pursue approval of their drug.  This was 
due to frustration with the review process, as Company 3 did not agree with VDD’s 
decision.  At this time, there was no avenue for Company 3 to appeal the decision, so 
they opted not to pursue the drug approval. 
 
Company 4 incurred direct costs totalling $3.38 million, which were the result of 
additional data requested by VDD and lost potential sales. 
 
  Company 4 incurred direct costs totalling $37,500 resulting from labour
20 costs 
required to compile additional data requested by VDD.    
                                            
20 Labour costs have been estimated at $37,500, the midpoint of the range of losses ($25,000-$50,000) 
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Company 5 incurred direct costs totalling $19.8 million, which were the result of lost 
potential sales and an additional clinical study requested by VDD. 
 
  Direct costs incurred by Company 5 include the additional clinical study 
requested by VDD when clinical data was available from research completed in 
another country.  This cost totalled $66,911 ($57,800 (study cost) compounded 
over three years).  
  Company 5 estimated potential sales for this product at $1 million, $1.7 million 
and $2.5 million for the first three years on the market, followed by approximately 
$6.75 million in sales every year after. The net present value of their estimated 




The costs to the agricultural industry for the five cases analyzed stem from the losses in 
efficiency and productivity resulting from not having the drugs available for use.  
 
Company 1 conducted studies that illustrate a decreased incidence of a livestock 
disease in calves treated with Product 1 compared to drugs that are currently available. 
These studies show that there is a substantial loss in cost savings of not having this 
drug on the market. The cost savings per calf equals approximately $12.50 (changes 
with yearly exchange rates). If all Canadian farmers were to treat cattle that become 
infected with this disease, and if Company 1 captures 15% of the market as it has 
estimated, the net present value of the lost cost savings since 2000 equals $7,832,002.  
 
Product 2 enhances the productivity of food animals.   The estimated per year loss to 
the industry of not having access to this product was calculated by determining the 
value of the increase in efficiency and multiplying these savings by the gross margin per 
unit. Given Company 2’s estimated market share of 45%, savings were calculated at 
$19.3 million. The net present value of this loss in efficiency gain (during the period 
Company 2 has been waiting approval) to the industry equates to $83.2 million.  
 
Product 3 is an antibiotic for the livestock industry that can be used to treat a number of 
common ailments. This type of drug is not new to the industry; in fact there are 
numerous other drugs that treat the same ailments.  For these reasons, it was not 
possible to estimate the impact to the agricultural industry of not having Product 3 
available.  The true benefit of Product 3 is qualitative in that it causes minimal reaction 
to the animal around the injection site.   
 
Because Product 4 is intended for use outside of livestock agriculture, it is difficult to 
estimate a dollar value of the cost to the industry of not having the drug available.  As a 
result, impacts to industry can only be described qualitatively.     
 
Product 4 is a treatment drug and there are no similar drugs available on the market. 
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‘compounds’ of active ingredients found in human medications that have been altered 
for animal use. Due to the inconsistency of these compounded drugs, there is little 
uniformity in treatment length and dosage. The primary advantage of Product 4 will be 
cost savings from fewer veterinarian visits and a faster return to training/performance 
due to the availability of a consistent and reliable drug.   
 
Because Product 5 is a drug intended for companion animals, it is difficult to estimate a 
dollar value from the impacts of not having the drug available.  As a result, impacts to 
industry can only be described qualitatively.     
 
The costs to pet owners of not having this drug available include increased veterinarian 
visits and the monetary and mental costs of the possible death of companion animals.   
 
LOSSES TO THE ECONOMY 
 
Company 1 downsized its labour force
21 by two account managers and two sales 
representatives, for an opportunity loss to the economy of $191,570.  In addition, 
Company 1 had originally planned to hire other new staff as a result of Product 1.  
 
No attempt was made to assess the impact of the loss of time under the patent for the 
compound.   
 
If Company 2 had received approval for Product 2, it was expected that they would do 
further research.   Their research expectations were in the range of $500-1,000,000, 
and have been estimated at a loss to the economy of $868,219 ($750,000 compounded 
from 1999). 
 
Company 4 expected to hire two senior level staff (salaries of $150,000) and eight junior 
level staff ($60,000 per year) that would have been required with the approval of this 
product. 
 
3.3.3  Case Study Summary 
 
Table 3.1 summarizes the economic impacts of VDD not approving these five products 
in a timely fashion in Canada.  These impacts include direct losses to companies, 
downstream losses to the agriculture industry and losses to the economy.  
 
Recall from the discussion of methods that the columns in the table cannot be added 
together to determine a total economic impact resulting from the five cases analysed.  
Individual categories (direct, downstream and economy) have been added across the 
cases to demonstrate the total direct losses (to companies) of $75.9 million, 
downstream losses to the agriculture industry of $91 million and losses to the Canadian 
economy of $1.8 million resulting from the five cases.   
                                            
21 There were also additional direct losses that could not be quantified (for confidentiality reasons) that 
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We note again, that in the cases of the products for companion animals, the injury 
cannot be measured in economic terms.  Thus our estimates are conservative.   
 
Table 3.1  Summary of Total Economic Impacts 
 
CASE 




Case 1  $21,617,257 $7,832,002 $191,570
Case 2  $11,858,200 $83,158,474 $868,219
Case 3  $19,493,313 N/A N/A
Case 4  $3,038,750 N/A $780,000
Case 5  $19,844,130  N/A N/A
Total Economic Losses  $75,851,650 $90,990,476 $1,839,789
 
Throughout the case studies there were consistent problems identified by several of the 
case study companies.  The following is a list of the common observations (Note that 
these are the opinions from the case companies, not the authors of this report): 
 
  The divisions within VDD did not communicate. 
  Reviewers bear no accountability for questions asked or research requested: 
o  Do not have to justify on a scientific basis for additional tests. 
o  There is no third party appeal mechanism that industry can use to 
question review requests for additional data that industry thinks 
unwarranted from a safety and efficacy standpoint (This comment was 
noted prior to the December 2003 blueprint for appeal mechanisms in 
Canada). 
  VDD consistently “changes their mind” on requirements, i.e., data or information 
requests. 
  VDD specifies a requirement for research but also approves the research design 
at a fee. 
o  This is a conflict of interest 
o  The Canadian regulator has become the “judge and jury” with a cost at 
each stage 
o  Cost recovery, as it is carried out in Canada conveys a perverse incentive 
to the regulatory body 
  Canadian product approvals are often considered a last resort after all other 
country approvals have been obtained.   
o  Approval process in Canada is thought of as cumbersome, expensive, 
time consuming and represents only one tenth of the product market. 
o  Canada’s questions can delay approvals for larger markets elsewhere. 
  VDD is inconsistent as to when they will use product trial data from other 
countries in reviews. 
  There has been a significant reduction in research and development within the 
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  Canada’s product approval process and personnel are risk adverse to product 
approval and technological advancement. 
o  Young reviewers in Canada are passing off regulatory responsibility (i.e., 
indecisive about making a decision) to academics. 
  Canada is not spending enough time updating their Maximum Residue Limits. 
Since this statement was identified, VDD has established 17 more MRLs/AMRLs, 
for a total of 67 in 2003.  VDD projects a total of 180 MRL’s/AMRL’s by mid 2004 
(VDD, 2003).   The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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4.0  Designing an Optimal System 
 
Section 4.0 describes the methods used to obtain information for the development of an 
optimal product approval system.  Specifically, section 4.1 describes the focus group 
process and section 4.2 describes the results from the day.  Section 4.3 puts the 
information into perspective and identifies potential solutions for a ‘tough but fast’ 
Canadian system. 
 
4.1  The Focus Group 
 
One of the intentions of the study was to provide direction on how to improve the current 
procedures so they are aligned with an optimum ‘tough but fast’ policy.  This was 
accomplished through a facilitated focus group session.   
 
On Thursday, April 10, 2003 the George Morris Centre facilitated a focus group 
discussion in Toronto to develop an ‘optimal’ regulatory system for Canada’s animal 
drug product approval.  The focus group brought together key members of the industry 
(industry personnel, producers, veterinarians and government) to help identify and 
develop the basic requirements for an optimum ‘tough but fast’ system in Canada.  The 
following is a list of the organizations that attended the focus group session: 
 
Industry 
•  Canadian Animal Health Institute 
•  Elanco Animal Health 
•  Novartis Animal Health Canada Inc. 
•  Bayer Inc 
•  Boehringer Ingelheim (Canada) Ltd. 
 
Producers 
•  Canadian Cattlemen’s Association 
•  Canadian Poultry and Egg Processors Council 
Veterinarians 
•  Linwood Veterinary Clinic 
•  Feedlot Health Management Services 
 
Government 
•  Canadian Food Inspection Agency 
•  Unfortunately Health Canada declined the invitation after repeated requests. 
 
Facilitation 
•  George Morris Centre 
 
The day began with a background presentation to provide participants with information 
on the regulatory approval systems in the United States, European Union, Australia and The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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Canada.   Discussion surrounding the perceived problems with the Canadian system 
and a Canadian product submission case study were also presented. 
 
Following the presentations, the participants were asked to separate into groups to 
brainstorm and provide ideas for an optimal Canadian system.  A workbook was 
provided that contained questions with respect to the Canadian product approval 
system.  Participants were also given a matrix of information of the key points from the 
regulatory systems of each of the countries discussed in the opening presentation (see 
Appendix B).   
 
There were six areas that the George Morris Centre identified as discussion areas.  The 
questions were developed to determine if the objectives of the Canadian legislation 
were appropriate, whether the procedures for market approval, applicant tasks and 
costs and incentives were appropriate, and whether the Canadian system was 
transparent and consistent.  The following are the specific questions used in the focus 
group discussion:  
 
1.  Objectives of the Legislation 
 
Are the current objectives of Canada’s legislation appropriate?  Does the legislation 
require adjustment?  If so, what should be added or removed?   
 
2.  Procedures for Market Approval - What the government requires for product 
  approval, for example, efficacy, food safety, manufacturing and compliance.  The 
  ‘procedure’ is the submission containing details on manufacturing, quality 
  control, residue and clinical studies. 
  
Are the procedures for market approval appropriate?  What, if anything, should be 
added or removed? 
 
3.  Applicant Tasks – The specific tasks required for approval.  For example, 
  submitting application, fees, and data from clinical studies. 
Are applicant tasks clear and consistent?  If not, how can the tasks be improved? 
 
4.  Costs and Incentives 
 
Is the cost structure appropriate?  If not, how can the government be made accountable 
for industry expense?  What incentives can be put in place to make the Canadian 




Would you say the current system lacks transparency?  Why?  Can it be transparent 
with the variety of science that must be addressed for approvals?  What is required for a 
transparent Canadian system? 
6. Consistency The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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Would you say the current system lacks consistency?  Why?  Can it be consistent with 
the variety of science that must be addressed for approvals?  What is required to 
ensure regulatory consistency? 
 
7.  What are the perceived costs and benefits of the system you designed? 
 
Dr. Larry Martin (CEO) and Cher Brethour (Research Associate) from the George 
Morris Centre facilitated the ‘optimal’ product approval discussion.  The next section 
describes the results from the focus group discussion. 
 
4.2  Results of the Focus Group Discussion 
 
The following is a synopsis of the brainstorming from the focus group session for each 
of the questions identified above. 
 
1.  Objectives of the Legislation 
 
When asked if the objectives of the Canadian legislation were appropriate, the 
consensus from the group was that they were, but the real problems were with the 
regulations, not the legislation specifically.  However, it was agreed that if the following 
were included in the legislation, the system would function more efficiently.  
 
•  Establish/publish Maximum Residue Limits at Notice of Compliance 
o  Without Maximum Residue Limits set by Health Canada, any amount of 
residue from a drug can be identified as a problem or cause for concern.  
As technology improves, more and more residues can be detected, i.e., it 
is now possible to detect residues at levels that could previously not be 
detected.  If there is no MRL established at notice of compliance, any 
residue is considered a problem.  This will hinder trade. 
o  Establishing MRL’s will protect and facilitate trade.   
•  Separate the companion animal and food animals in the legislation 
 
2.  Procedures for Market Approval 
 
The following processes were identified as being fundamental for an optimal, efficient 
and fair system in Canada. 
 
•  Pre-submission meetings. 
o  To determine specific requirements for the application in advance.  The 
meetings may also serve as an opportunity to discuss the types of data 
required and testing or laboratory procedures to be used. 
o  Being able to identify as an applicant what will be usable in the submission 
when designing trials. 
o  The intent is to involve the reviewer at an early stage of the process. 
•  Independent appeal process for all stages of the review. The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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o  The applicant has the ability to appeal scientific decisions made at any 
stage of the submission through a tiered process that would include 
independent arbitrators. 
•  Politics or the precautionary principle should not be a part of the approval 
process.  
•  Human Resource management. 
o  Ensuring that there is enough qualified staff at Health Canada (specifically 
Veterinary Drugs Directorate) whose primary function is reviewing 
submissions.   
o  Minimize how often review staff are pulled from their jobs to work on other 
projects.  
•  Harmonization of approval process. 
o  At a minimum accept reviewed studies from referenced jurisdictions. 
o  Share comment notes from reviewers in other jurisdictions – onus would 
be on the sponsor. 
  May require a Memorandum of Understanding. 
 
3.  Applicant Tasks 
 
The following suggestions were made to improve the application process for Canadian 
submissions to make them more clear and consistent. 
 
•  The approval systems should be based strictly on evidence based science. 
o  Develop a decision tree to make scientific decisions. 
•  Industry training on regulatory issues, and regulatory training on industry issues. 
o  Better understanding and trust for users of products and industry. 
•  Current guidelines and policies. 
o  Joint consultations --- consistency for both industry and reviewers. 
o  Since the focus group in April 2003, VDD has developed four “Guidance 
for Industry” documents published on the VDD website January 13
th: 
•  Preparation of Veterinary New Drug Submissions. 
•  Preparation of Veterinary New Drug Submissions:  Clinical Safety 
and Efficacy Requirements. 
•  Preparation of Veterinary New Drug Submissions:  Human Safety 
Requirements. 
•  Preparation of Veterinary New Drug Submissions:  Manufacturing 
and Quality Control Requirements.  
(VDD Guidance for Industry, 2003) The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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4.  Costs and Incentives 
 
The following points were identified to make the cost structure for product approval 
more efficient. 
 
•  Fees should be consistent with VDD performance delivery, industry market size 
and competitive with regulatory programs in developed countries that Canada 
competes with.   
•  Health Canada reviewers performance should be measured against the 
objectives of the Business Coalition on Cost of Recovery
22. 
•  Phased payment for phased reviews. 
 
The following points were identified to make incentives for product approval more 
efficient. 
 
•  Better connections between government and industry.  
o  This includes but is not limited to, pre-submission meetings, annual 
meetings, global regulators, and corporate reviews to identify new 
technology. 
•  Clear performance targets and standards set with objective reviews by Health 
Canada management staff. 
•  Performance tracking to monitor adherence to the standards. 
 
5.  Transparency 
 
When asked if the Canadian system was transparent, the consensus among the group 
was that it was not.  The following ideas were provided to help improve transparency:  
 
•  A submission tracking system similar to the Therapeutic Products Directorate. 
o  One spokesperson in each review bureau responds to requests 
concerning submissions.  Manufacturers fax or email their status requests 
to the contact person who is then obligated to respond within 72 hours. 
o  Applicants should have a system to check the status of their submission 
by using a login and password on the Internet. 
•  Develop standard operating procedures for regulators and reviewers.  
•  Performance targets and regular reporting. 
o  Develop a set of clear performance targets and standards with objective 
reviews by management. 
•  Performance information on products made accessible. 
o  Generate report cards on products that are made public. 
                                            
22 The Business Coalition on Cost Recovery (BCCR) was founded in 1998 to address user fees as part of 
the government Cost Recovery Program.  The BCCR includes over 20 of Canada's leading business 
organizations representing large, medium and small businesses in a diverse range of sectors of the 
Canadian economy. The combined membership of the Coalition employs over 2.2 million Canadians and 
is directly responsible for over $330 billion in economic activity annually. The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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o  Access by users to data and information about products, e.g., 
veterinarians can obtain information on products. 
 
6.  Consistency 
 
When the group was asked if the Canadian regulatory system for product approvals 
was consistent, the group felt it was not.  The following ideas were provided to help 
improve consistency:    
 
•  Have consistency across regulatory agencies.  The same type of information 
and standards should be used in all jurisdictions, for e.g. Canada could 
become part of the international harmonization effort of VICH.  
o  VICH – International Cooperation on Harmonization of Technical 
Requirements for Registration of Veterinary Products.  It is a trilateral 
programme (EU-US-Japan) aimed at harmonizing technical 
requirements for veterinary product registration.  The program was 
officially launched in 1996 and Canada’s current status is as an 
‘observer’. 
  Since the focus group in April 2003, VDD has adopted and made 
effective (on November 1, 2003) 27 VICH guidelines for Canada 
(VDD VICH Website, 2004). 
•  Knowing what will be usable in the submission when they are designing trials. 
 
7.  Perceived Costs and Benefits 
 
The following is a list of the perceived costs and benefits of the ‘optimal system’ 
designed by the focus group participants: 
 
•  Less costs from the increase in throughputs of products. 
•  Trade issues would be avoided with resulting user benefits. 
•  Overall increase in food safety.  
•  With more assurance and availability of products animal welfare would improve 
from healthier livestock and reduced mortality.  
•  Predictability in investment and staffing decisions for industry submitting 
applications for approval. 
•  Research and Development incentives for Canada if the system is tough but 
fast, an example might include a tax credit system amenable to Research and 
Development.  
•  Develop image of Canada as a great place to do research.  The industry is small 
enough to evoke change and there is already the skill set and facilities in place. 
 The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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4.3  Summary of Focus Group 
 
The purpose of the focus group was to bring together key members of the industry 
(industry personnel, producers, veterinarians and government) to brainstorm and 
develop improvements to the current approval procedures so they are aligned with an 
optimum ‘tough but fast’ product approval system in Canada.   
 
The focus group session and questions drew out several recurring concerns about the 
Canadian regulatory system.  The most noticeable was the need for pre-submission 
meetings and an appeal process or dispute mechanism.  It is believed that pre-
submission meetings will allow applicants to ask questions, prepare more appropriately 
for the submission (which could speed up the process) and help to make budgeting 
decisions as a business.  It was also expressed that a third party appeal that is 
applicable throughout the decision process, would allow applicants the opportunity to 
express their concerns with decisions. 
 
Participants also felt strongly that harmonization of regulatory approval processes in 
Canada (e.g., VICH) would prevent applicants from having to ‘reinvent the wheel’ for 
Canadian submissions.  This would also increase the likelihood of research and 
development in Canada.  Another suggestion to speed the review process was to share 
the regulatory review comments that were already generated by countries that had 
already approved the product. 
 
The final suggestions all related to the submission review.  Participants felt strongly that 
decisions should be based on evidence-based science and that the influence of politics 
and the precautionary principle should be left out of the review process.  It is understood 
that in some circumstances politics may be a factor in the final approval, however, 
politics should never impact the reviewer’s recommendations.   
 
It was also noted that there continues to be staffing concerns within Health Canada.  
There is concern that there is not enough reviewers and that those that are reviewing 
are not following a standard operating procedure.  The last suggestion was that a 
submission tracking system be put in place to allow applicants the ability to track the 
status of their submission.  This would enable companies to keep track of their 
submission and to make business decisions accordingly. 
 
Finally, it was felt that a Maximum Residue Limit should be assigned at the ‘Notice of 
Compliance’ stage, to protect Canada’s trade position. 
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5.0   Conclusions and Recommendations 
 
There were two key purposes to this project:  
 
1.  Identify the impact of Canada’s product registration system on companies 
operating in the animal health products industry in Canada, and ultimately, 
determine the economic cost to the agri-food sector and the Canadian economy 
imposed by this system; and  
2.  Offer some alternative, potentially “optimum,” solutions to the system and identify 
the costs/benefits of such a system. 
 
The specific objectives are as follows:   
 
1.  To describe, compare and contrast the agriculture product approval systems in 
the United States, Australia, European Union and Canada with respect to the 
governing authority, structure and responsibility, marketing approval, applicant 
tasks, fees, time to approval and performance indicators. 
2.  To estimate the direct loss to companies, downstream losses to the agriculture 
industry and losses to the Canadian economy resulting from delayed product 
approval for five case study products submitted to the Veterinary Drugs 
Directorate for approval in Canada. 
3.  To develop recommendations based on the above analysis for improvements to 
the Canadian system. 
 
Below are the summary and conclusions from this study. 
 
5.1  Summary and Conclusions 
 
Regulatory systems, almost by definition, impose costs on the private sector.  Their 
major intent is to require people to do things in the public interest that might not be done 
absent the regulation.  As a result, they may be viewed as extra costs imposed by 
society, that society is willing to pay to manage risks.
23  
 
Thus, the economic impacts about which society should be concerned in a regulatory 
system are inherently “comparative” or “relative” – i.e., one always asks, compared to 
what or whose regulatory system?  Underneath this is the fundamental question, is this 
regulatory system doing an efficient and effective job of managing the risks to society? It 
is not possible to answer this question in absolute terms because to do so would require 
knowledge of the “perfect” system, against whose costs we could compare the 
Canadian system.  The perfect system for product registration is not known. 
 
                                            
23 Of course, if the regulatory system prevents poor products or practices from occurring, then the “costs” 
may be short term in nature, compared to the long-term costs that would have arisen absent the 
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However, by attempting to understand the structure and performance of product 
registration systems in other countries, our intent in this project was to provide a general 
comparison.  Many Canadians tend to compare our systems with the US.  This is quite 
relevant in this case because of the close links in products and in the markets of the 
downstream livestock and meat industries. In this study, we undertook a rather detailed 
description and comparison of performance of the animal product registration systems 
in the US and Canada.  We also examined the systems in the European Union (EU) 
and Australia.  The EU was chosen because it is one with which many companies deal 
who are also involved in the Canadian market, and one that provides access to a 
potentially large market for animal health products. 
 
Australia was chosen because, like Canada, that country represents a relatively small 
market.  In addition, preliminary research indicated it made major structural changes to 
its product registration system a few years ago.  Therefore, it seemed a likely candidate 
to provide some lessons.   
 
Examining the structure and performance of the alternative systems, which is done in 
section 2.0 and responds to objective one, provides a number of interesting insights: 
 
•  There are substantial structural differences in the systems among the countries.  
For example, in some the intent of the legislation that creates them is to protect 
health.  In others, it includes a health protection component, but also has 
objectives that relate to trade, thereby requiring regulators to explicitly consider 
the balance.    
 
•  Other structural differences in the systems (among the countries) include internal 
disciplines designed to facilitate approval processes.   
o  For example, until recently there was no appeal mechanism in Canada 
during the application process or once the drug decisions were made, but 
they exist in other systems.  In December 2003, a blueprint for appeals 
was published by VDD; however, it is not an independent appeal 
mechanism as requested by industry.  There still remains a need for an 
independent dispute mechanism. 
o  For example, there are no mandatory pre-submission meetings (as in the 
EU) for applicants to get an understanding of what is required prior to 
submission.  It should be noted that these problems refer to the Veterinary 
Drugs Directorate, not the Veterinary Biologics Section (VBS).  The VBS 
does have set performance standards, generally meets performance 
standards and tends to be transparent and consistent in delivery of its 
services.   
 
•  At least one country, Australia, has taken a benchmarking approach in one 
component of its product registration process (pesticide registration) and has 
been named “world’s best practice” by reviewers. One review of the Australian 
system indicates that, in addition to superior performance in terms of time to The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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make a decision, its openness and transparency have additional advantages: 
 
o  There was improved industry compliance with registration requirements due 
to better information and feedback; 
o  Decisions about active constituents and chemical products were made within 
statutory framework; 
o  Registered products in the marketplace meet legislative requirements for 
performance and safety due to sound decision-making. 
 
•  There are substantial differences in fees charged by regulators.  Canada’s is 
among the highest, especially per unit of market access that can be gained. 
o  Some progress has been made regarding Canadian fees through Bill C-
212, a private members bill (passed unanimously through the House of 
Commons in September 2003 and will likely go to Senate in February 
2004 for consideration).  The bill would require fee-charging federal 
departments and agencies to consult with stakeholders prior to 
establishing a fee; show that a clear private benefit is linked with the fee; 
establish an independent resolution system; and, set performance 
standards in exchange for the fee charged.  The Bill would also provide 
fee reductions when performance standards were not met.   
 
•  There appears to be greater unanticipated delays in the approval system in 
Canada than in the other comparators. 
 
•  Total elapsed time until a decision is made is the slowest in Canada, by a wide 
margin.  It is understood that, since the commission of this report (January 2003), 
there has been an effort on the part of the VDD to improve this situation but more 
improvements are needed to make this a world-class regulatory environment.  
o  The Canadian system, like the US, makes no commitment about time of 
approval decision and does not adhere to its internal administrative 
standards. 
  Canada has an administrative or “provisional” standard of 180 
days.  
  US currently have a 180-day provisional standard.  However, they 
have implemented the Animal Drug User Fee Act (ADUFA) in which 
the legislation will impose performance standards on the CVM that 
are expected to improve the drug approval process to 180 days, 
90% of the time by 2008. 
  Australia aims to finish an approval in 240 days. 
  The EU attempts to complete an approval process in 210 working 
days, not including “clock stop” days. 
o  Actual elapsed time until a decision was made in Canada is not related to 
the administrative standard.  
  Canada: exceeded its 180-day target 87% of time (2002). 
  US:  exceeded its 180-day target 83% of the time (2002). 
  Australia: met its 240-day target 96.2% within timeframe (2001-02). The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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  EU: limited data, but in the last 3 yrs has generally been within its 
timeframe. 
o  It is important to acknowledge that Canada’s system has undergone 
substantial change over the past few years, especially with respect to 
obtaining more resources, and all the results of those changes have not 
been manifested.  Nevertheless, it is also true the data suggest that the 
time to make a decision continues to increase, except in some categories 
where a backlog could be cleaned up relatively quickly. 
 
As one way of gauging the costs of the Canadian animal health product registration 
system, five case studies submitted to us by animal health companies were analyzed to 
estimate the costs (Section 3.0, Objective 2) imposed as a result of the additional time 
required to get to a decision beyond the best performer – i.e., Australia.  Costs were 
categorized into direct impacts to the companies sponsoring the applications, indirect 
costs to the downstream industries, which are unable to source the product and its 
health benefits, and finally losses to the economy.  The losses range from 
approximately $76 million in direct losses to the participating companies, $91 million in 
indirect downstream losses to the agriculture industry and $1.8 million in losses to the 
economy.  Note that the categories cannot be added together to determine a total 
economic impact, as it would result in double counting.  Specifically, part of the direct 
losses to manufacturers is measured by lost sales, while the losses downstream are 
measured as lost productivity.  If the two values were added together, it would double 
count the loss because in order for industry to obtain the productivity gains they must 
purchase the product from the manufacturer.  By purchasing the product, the 
manufacturer no longer experiences the loss in sales.   
 
We make no claim that the cases are a representative sample of what this industry 
faces in attempting to obtain product approval.  Therefore, we know of no way to project 
the losses to an industry level.   On the other hand, 90% of Canadian decisions are not 
completed within the timeframe set by the Directorate’s internal guideline, and over 90% 
were completed within the time required by the Australian system.  Therefore, while we 
cannot project the cost of the system to the agri-food industry level, it is clear that the 
losses are large.  As indicated at the end of section 3.0, the issues uncovered by the 
case studies include:  
 
  The divisions within VDD do not appear to communicate. 
  Reviewers appear to bear no accountability for questions asked or research 
requested: 
o  Do not have to justify on a scientific basis for additional tests. 
o  No third party to appeal nuisance research requirements. 
o  There is the need for a tribunal (this comment was noted prior to the 
December 2003 blueprint for appeal mechanisms in Canada). 
  VDD reviewers have consistently “changed their mind” on requirements, i.e., data 
or information requests. 
  VDD specifies a requirement for research but also approves the research design 
at a fee. The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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o  This is a conflict of interest. 
o  The Canadian regulator has become the “judge and jury” with a cost at 
each stage. 
o  Cost recovery, as it is carried out in Canada conveys a perverse incentive 
to the regulatory body. 
  Canadian product approvals are considered a last resort after all other country 
approvals have been obtained.   
o  Approval process in Canada is thought of as cumbersome, expensive, 
time consuming and represents only one tenth of the US product market. 
o  Canada’s questions can delay approvals for larger markets elsewhere. 
  There has been a significant reduction in research and development within the 
Canadian divisions of the companies. 
  Canada’s product approval process and personnel are risk adverse to product 
approval and technological advancement. 
o  New reviewers in Canada are passing off regulatory responsibility to 
academics because they are indecisive about making a decision. 
  Canada has not been committed to updating their Maximum Residue Limits. 
 
These, the magnitude of losses in the case studies, and Canada’s relatively poor 
performance compared to other jurisdictions suggest that the system imposes very high 
costs. 
 
With the preliminary results of the foregoing as background, a group of industry, and 
government met to initiate the design of the characteristics of a stringent, yet timely 
product registration program for Canada.  The group came up with a lengthy and 
detailed set of characteristics organized around the following headings that are 
presented in Section 4.1 (Objective 3): 
 
•  Objectives of the Legislation 
•  Procedures for Market Approval  
•  Applicant Tasks 
•  Costs and Incentives 
•  Transparency 
•  Consistency 
•  Perceived Costs and Benefits  
 
While the foregoing are discussed in detail in section 4.0, one conclusion arrived at by 
the assembled group is inappropriate given subsequent information.  That conclusion is 
that the underlying legislation does not need to change.  Subsequent work by Rainnie 
and the Environmental Commissioner (described below) reveals what was already 
becoming evident to the Centre through a number of anecdotal observations – the 
problems are not just in approvals of animal health products.   
 
As Rainnie and the Environmental Commissioners reports show below, the 
problem is widespread in approval of plant health products, and in approval of 
consumer (companion animal) products.   The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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A similar frustration in the pesticide approval and regulatory system was highlighted in 
the most recent report of the Commissioner of the Environment and Sustainable 
Development released in October 2003 (Office of the Auditor General, 2003). The report 
contains a number of criticisms of the Canadian Pest Management Regulatory Agency 
(PMRA) and its approval processes. A number of these criticisms resemble those that 
were uncovered in this investigation of the approval processes of VDD within Health 
Canada.  The major findings contained in the section on pesticide regulation focus on 
the inconsistent framework for registering pesticide approvals, the inability of PMRA to 
meet its own decision and approval targets for new pesticides as well as minor use 
pesticides, and the human resources issues that have caused problems within PMRA 
similar to those within the VDD.  
 
The inconsistency in the framework for registering pesticide approvals is very similar to 
the inconsistencies in the processes at VDD. The Environmental Commissioner notes 
that in some cases steps were skipped, but in others a substantial amount of additional 
information was requested.  The conclusions of a comparative study conducted by D.J. 
Rainnie at the Atlantic Veterinary College agree (Rainnie, 2002). Their study compared 
the regulatory requirements of the Centre for Veterinary Medicine (CVM) in the United 
States to VDD with respect to drugs for use in companion animals. Rainnie concluded 
that although the regulatory requirements for both agencies are essentially the same, 
the CVM documents that lay out the requirements are more specific, numerous and 
detailed and therefore are less open to interpretation and resulted in more consistency 
in CVM reviews. The inconsistency in reviews at VDD found in the case studies during 
this investigation highlights this finding from Rainnie’s report.  
 
Rainnie’s report also highlighted that the CVM was more formally standardized and less 
flexible in all processes throughout the approval process. Therefore, quality control and 
consistency in the approval process was always higher in CVM when compared to 
VDD.  Rainnie also found that the review process at CVM to be team oriented, but at 
VDD it was more individualistic. This highlights our finding regarding the human 
resources issues at VDD and their capacity to prolong the approval process. Finally, 
Rainnie found that the interpretation of data from the field studies was generally the 
same in both agencies. This finding should encourage more collaboration between the 
two agencies thereby reducing any recreation of field data and reducing the amount of 
time required during approval decision process. 
 
Overall, Rainnie’s report (2002), the Report from the Environmental Commissioner 
(2003), and this study illustrate that the product approval process in Canada, in more 
than one industry, requires reform so that Canadian industries can continue to remain 
competitive. 
 
When one views the entire product approval system, one is left with the impression that 
it is out of the control of Parliament.  The legislation and regulations have been 
developed piecemeal.  There is no – or very little - reference to any economic or trade 
objectives of the legislation.  Product reviewers, therefore, do not balance the narrow The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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concept of risk prevention with the promotion of innovative advancements in health 
methodologies and products.  By the same token, there is very little in the legislation 
that allows the public, though Parliament and its organizations such as the Auditor 
General, to hold regulators accountable for the economic consequences of their 
decisions -or non-decisions.  At a time when government says it wants to increase 
“value adding”, “productivity” or “technology”, it must put regulatory processes in place 
that are consistent with its intents.   
 
Therefore, our recommendation below goes farther than did the participants (in Section 




This study documents in a systematic way the issues with and improvements made by 
the animal health product approval system in Canada.  Despite the changes made to 
date (which was well documented in the Director General’s presentation to CAHI’s 
annual meeting in June 2003 (Kirkpatrick presentation slides at CAHI Annual Meeting, 
2003)), gains in review times have not yet resulted and costs remain high.  Anecdotally, 
we are told that some companies increasingly choose not to bother registering products 
in Canada, thereby depriving the downstream industries of economically valuable 
products.  It also reduces the animal health industry’s investment in Canadian research 
institutions. 
 
As a result of our participation in this study, it has clearly come to our attention 
that the entire agri-food sector is extremely upset with the product registration 
process in Canada.  Work with a group of input supply industries this year 
resulted in substantial concern with plant product registrations, pesticide 
registration, vitamin and mineral registration in animal feeds, and even issues in 
the fertilizer industry. These issues from the “supply side” are echoed by farm 
organizations that are frustrated with the limited access to products available in 
competitor countries that are more effective, friendlier to animals and the 
environment, but are not available to Canadian customers.  More recently, we 
were told by food processors that the issues on registration of inputs is word-for-
word interchangeable with their problems in getting food products registered and 
labels approved. 
 
If all of this is as true for the other industries as it is for animal health, then the 
inescapable conclusion is that this is not just a problem with VDD.  The attitude and 
actions that so clearly frustrate the animal health industry, is consistent with a general 
culture that has developed in the product approval bureaucracy.  
 
Our recommendations come in two areas: first, what should be done to reform the 
system and what characteristics it should have; and second, what the process should 
be to make it happen. 
 The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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5.2.1  Changes to the System   
 
1.  Parliament needs to change the legislative intent to include a goal of 
enhancing industry competitiveness as well as protecting animals, people and 
the environment.  They are not in conflict – no company will gain economic 
advantage for long by abusing animals, people or the environment. In fact, 
everyone we know is looking for advantages by trying to do the right things, in 
part because it is perceived to be part of what most consumers want.  
Therefore, everyone will welcome an approval system that is tough but fast.   
2.  Parliament needs to extend this change across all product approval 
legislation, at least in the agri-food sector.  The same problems occur for plant 
health, other input supplies and food labelling.  
3.  The system should: 
•  Be transparent – applicants must be able to understand from the 
beginning what information is required to obtain an approval. Therefore, 
the regulatory procedures need to explicitly have clear guidelines for what 
is required of the applicant and what is required of the regulator. 
•  Be consistent – the same things should be expected for a certain type of 
registration every time. The current system is full of arbitrary decisions by 
regulators that mean each application is a new adventure.  
•  Have well-understood timelines. They should be measurable and 
enforceable.  They should likely include a “stop clock” concept so that both 
sides are accountable. 
•  Have clearly defined gates (e.g., specific issues dealt with separately, i.e. 
it should be clear what the procedures and decisions are for trade issues 
separately from efficacy, separately from health, environment, etc.). 
•  Function on fact-based processes. 
•  Be properly resourced by government, including optimum use of 
appropriate outside expertise. 
•  Include independent appeal mechanism(s). 
•  Develop appropriate benchmarks and metrics to measure its performance 
against objectives and compare to best in class. 
 
5.2.2  Process for Change 
 
The process clearly needs to pursue a number of efforts simultaneously: 
 
1.  Most fundamentally, CAHI needs to join forces with other segments of the  
agri-food sector to effect change since all are negatively affected by the larger 
system.  This coalition also needs to get some form of consumer support for the 
principles.  It needs to develop a united front and convince elected government to 
effect the changes. 
2.  Our experience is that the case studies are excellent vehicles to make the issues 
real for people who don’t deal with product registrations every day.  They clearly 
show the faults with the system and the frustrations that result.  In addition, they The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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provide a way to describe the magnitude of cost.  A number of them need to be 
done in the other industries to assist in communication from a consistent 
framework. 
3.  In order to move forward, it is likely that the following initiatives need to be taken: 
a.  Contact potential champions among elected representatives to develop a 
strategy for convincing government of the need for change. 
b.  Contact the people in the “Smart” Regulation process to obtain their 
understanding and support (this has already started). 
c.  Bring together the affected industries in a series of conferences to 
establish common ground for the push to get change. The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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APPENDIX A – Case Study Interview Question Guide 
 
Background on Company and Product 
1.  What range of products do you produce/market. 
2.  Is the product we’re discussing marketed or up for approval elsewhere? 
3.  Was the product we’re discussing developed in Canada? 
 
Activities in Seeking Approval 
1.  At what point, internally, was the decision to seek Canadian registration made 
and action initiated? 
2.  At that time, did it appear clear what submissions would be required to obtain a 
Health Canada approval decision?  Did they indicate the likely time period within 
which an approval decision would be made at the time it was initiated?  Did they 
indicate a likely cost?  
3.  What materials were provided to Health Canada? 
4.  What time, effort and direct cost can be associated with the materials submitted 
to Health Canada? 
5.  Were other materials requested after the initial submission?  How long after the 
initial submission was the request from Health Canada received?  What time, 
effort and direct cost can be associated with these materials? 
6.  Was an approval decision made?  What reporting was provided by Health 
Canada during the approval process?  What reporting was provided at the time 
of the approval decision? 
 
Product Approval Experience Elsewhere 
1.  Where else have regulatory approvals been initiated for this product? 
2.  Has an approval decision been made in these jurisdictions? 
3.  Did the regulatory body indicate the likely time period within which an approval 
decision would be made at the time it was initiated?  Did they indicate a likely 
cost? 
4.  What materials were provided to the regulatory agency? 
5.  What time, effort and direct cost can be associated with the materials submitted 
to the regulatory agency? 
6.  Were other materials requested after the initial submission?  How long after the 
initial submission was the request from the regulatory agency received?  What 
time, effort and direct cost can be associated with these materials? 
7.  What reporting was provided by the regulatory agency during the approval 
process?  What reporting was provided at the time of the approval decision? 
 
Conclusions 
1.  What expectations did you have regarding the regulatory approval process in 
Canada when the product approval was initiated? 
2.  Did your expectations influence your decision to seek product approval? The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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Application Assessment Timeline for New Drug Submissions 
 
*Days in all cases are business days, except EU where days are actual working days. 
 











•  The 180 days to reach a decision is an administrative standard and is not necessarily adhered to. 
 
 
The United States – Center for Veterinary Medicine 
 
Days 














Application  Must inform applicant of
progress. Only a
“provisional timeframe” The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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Change or Repack 
New Product, approved active 
– new situation. 
Worst-case category – 
Required to have approval 






assessment report – without 
confidential aspects.
Clock Stop – CVMP 
drafts questions and 
overall conclusions.  
Sent to applicant. 
Clock restart – (on 11 official










Restart Clock – Oral
explanation by applicant. 
CVMP Decision and draft 
Assessment Report. 
Final translations of packaging
inserts and labeling. 
Finalization of Assessment Report in 
consultation with applicant. The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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Note:  Acronyms are defined at the bottom of the matrix. 
 
  REGULATORY MATRIX:  Agricultural Product Approvals 
 Canada  Australia  US  EU 
OBJECTIVES OF THE SYSTEM 
 
What 
•  Ensure drugs sold in Canada 
are safe and efficacious for 
animals  
•  Ensure safety of food for 
humans and animals  
 
•  Establish openness and 
transparency in decision-
making process 
•  Evaluate, register and 
regulate agricultural and 
veterinary chemicals 
•  Ensure animal drugs are 
safe and effective for their 
intended use and that they 
do not result in unsafe 
residues in food 
•  Contribute to the protection 




•  Approved for sale if 
o  Safe for animals and 
effective for purpose 
o  No harmful residues 
o  Manufactured according to 
specifications 
 
•  Must be satisfied that there is 
no risk to: 
o  Consumers 
o  Administrator of product 
o  Environment 
o  Target animal/crop 
o  Trade in an agricultural 
commodity 
•  Product must work effectively 
for specified use 
•  Authorities include: 
o  Approving NADA & 
INAD applications 
o  Issue notices, 
proposals, orders to 
refuse to approve 
applications 
o  Approve certain food 
additives 
•  By mobilizing scientific 
resources to provide high 
quality evaluation of 
medicinal products, advice 
on research and provide 
useful information to users 
and health professionals. 
•  By developing efficient and 
transparent procedures to 
allow timely access by users 
•  By controlling the safety of 
medicines for humans and 




•  Receive approval based on 
three components: 
o  Efficacy 
o  Food Safety 
o  Manufacturing and 
Compliance 
•  Assess approval based on: 
•  Safety 
•  Efficacy 
•  Impact on environment 
and trade 
•  FDA approval on basis of: 
•  Quality 
•  Safety  
•  Efficacy 
•  Decisions should be based 
on: 
o  Quality 
o  Safety 
o  Efficacy 
•  Concerned to the exclusion 




•  Submit ‘New Drug Submission’  
o  Contains details on 
manufacturing, quality 
control, toxicity, 
pharmacology, residue and 
clinical studies. 
 
•  4 steps for assessment 
o  Toxicology evaluation 
o  MRL and WHP 
evaluation 
o  Dietary exposure 
evaluation 
o  Public consultation and 
•  Submit NADA or INAD 
application 
•  Review by ONADE to 
ensure submissions 
contain adequate and 
correct information and 
meet guidelines, i.e. 
•  Scientific evaluation of 
application by CVMP 
o  Scientific opinion 
prepared 
•  Opinion sent to EC, draft a 
decision 
•  Consultations by EC with The Competitiveness Impacts of Canada’s Agricultural Product Review Regulations 
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  REGULATORY MATRIX:  Agricultural Product Approvals 
 Canada  Australia  US  EU 
liaisons  product is safe and 





•  Approval given to producers if 
various criteria are satisfied 
 
•  Extensive data package must 
be prepared and must 
establish that a chemical 
product is safe and effective 
•  Must comply with accepted 
scientific principles 
•  Applicants apply for 
approval when they feel 
that sufficient data has 
been generated 
•  For Community Marketing 
Authorizations, must meet 
criteria as listed in parts A 
and B of the Annex to (EEC) 
2309/93, which include new 
and innovative products at 
discretion of applicant, or 




•  Producer must provide proof 
(via data/clinical tests) that: 
o  Evidence to support 
efficacy, safety & quality. 
o  Drug is safe for animals 
and effective for intended 
purpose 
o  Does not leave potentially 
harmful residues 
o  Drug will be manufactured 
according to strict 
specifications 
o  Directions on labels that 
are adequate & include 
withdrawal periods. 
•  Extensive product 
development, testing and field 
trials 
•  Consultations with review 
committees to ensure all data 
is correct and sufficient 
•  Information on the following 
must be supplied with the 
application: 
o  Chemistry and 
manufacturing 
o  Toxicology 
o  Metabolism and kinetics, 
residues (incl overseas 
trade aspects) 
o  Occupational health and 
safety 
o  Efficacy and target 
animal safety 
o  Environment  
•  Sponsors must conduct 
tests to show that: 
o  Drug is safe for target 
animal 
o  Drug has intended 
effect 
o  Edible products 
derived from treated 
products are safe for 
human consumption 
•  Need authorization from 
FDA for investigational 
drugs used on animals for 
human consumption 
•  Pre-submission meetings 
are stressed  
o  It is a vital opportunity 
for applicant to obtain 
procedural, regulatory 
and legal advice from 
the EMEA 
•  Application dossiers must 
include: 
o  Appropriate fees 
o  Expert reports, including 
required annexes (i.e. 
Part A or B) 
o  Applications for MRL if 
necessary 
o  Manufacturing and 
batch testing 
information 
o  European Drug Master 
File, if exists 
o  Specimen or mock-up of 
sales presentation of 
product 
o  Proposed Package 
Insert 
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  REGULATORY MATRIX:  Agricultural Product Approvals 
 Canada  Australia  US  EU 
language requirements 
COSTS AND INCENTIVES 
 
What 
•  Fees for a new drug 
submission range between 
C$25,660 – $70,200  
•  Administrative timeframe for 
VDD is 180 days, 90 days for 
corporate or brand name 
changes 
•  Fees for a new active drug 
submission (primary 
application) are $20,060 AUD 
(~ C$17,653) 
•  Assessment Period for a new 
active drug is 15 months (450 
days). 
•  Fees – November 2003 
ADUFA Act passed to 
collect fees for certain 
applications. 
•  Fees for NADA will range 
for from C$40,562 – 
C$81,124 
•  180 day provisional 
timeframe.  ADUFA Act will 
impose performance 
standards 
•  Fees for a new drug 
submission are ~ 100,000 
EUR (~C$157,000) (under 
review) 
•  Timeframe – 210 day 
assessment framework, 
which is on average real 




•  In December 2003, a blueprint 
for appeals was published by 
VDD; however, it is not an 
independent appeal 
mechanism as requested by 
industry.  There still remains a 
need for an independent 
dispute mechanism. 
•  15 months (450 days) is 
allowed for in legislation 
•  Companies may apply for a 
partial rebate of application 
fee if timeframe not met 
•  Appeal Process is in place - 
written request to reconsider 
decision. 
•  By law, the CVM must 
notify applicant of status of 
application after 180 days, 
regardless if a decision has 
been made or not 
•  Appeal Process is in place 
– once appeal is received 
a decision must be 
rendered within 40 
calendar days  
•  No fines for not meeting 
timeframe, but base 





ADUFA:  Animal Drug User Fee Act 
EEC: European Economic Community 
NADA: New Animal Drug Application (US) 
INAD(A): Investigational New Animal Drug Application (US) 
MRL: Maximum Residue Limits 
WHP: Withholding Period 
ONADE: Office of New Animal Drug Evaluation (US) 
CVMP: Committee for Veterinary Medicine Products (EU) 
EC: European Commission 